<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">

<head>

	<!-- Global site tag (gtag.js) - Google Analytics -->
	<script async src="https://www.googletagmanager.com/gtag/js?id=UA-61606930-1"></script>
	<script>
	  window.dataLayer = window.dataLayer || [];
	  function gtag(){dataLayer.push(arguments);}
	  gtag('js', new Date());

	  gtag('config', 'UA-61606930-1');
	</script>
	
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<title>Docking SARS-CoV-2 @ Drug repurposing</title>
	<meta name="keywords" content="Docking, drug, repurposing, Vina, Autodock, Affinity energy">
	
	<meta name="description" content="RNASA-IMEDIR project to open docking results in SARS-CoV-2 research.">
	<meta name="author" content="Cristian R Munteanu">

    <link rel="stylesheet" type="text/css" href="https://cdn.datatables.net/1.10.19/css/jquery.dataTables.min.css">
    <script type="text/javascript" language="javascript" src="https://code.jquery.com/jquery-3.3.1.js"></script>
    <script type="text/javascript" language="javascript"
        src="https://cdn.datatables.net/1.10.19/js/jquery.dataTables.min.js">
	</script>
	
	<!-- File included -->
	<link rel="stylesheet" type="text/css" href="default.css">
	<link rel="preload" as="document" href="extras/repurposing_boxplot_byTargets.html">
	<link rel="preload" as="document" href="extras/repurposing_AE_LigandByTarget.html">
	
	<!-- Dynamic table -->
	<script type="text/javascript" language="javascript">
    $(document).ready(function () {
        var myTable = $('#example').DataTable();
        $('#example').on('click', 'tbody td', function () {
            myTable.cell(this).edit();
        });
    });
	</script>
</head>

<body>
	<!-- Header menu -->
	<div id="logo">
		<h1><span>Docking <img alt="logo" src="images/logo.png" height="25" width="50"> SARS-CoV-2</span>
	</div>
	
	<!-- Menu options -->
	<div id="header">
		<div id="menu" class="container">
			<ul>
				<li><a href="index.html" accesskey="1" title="">Home</a></li>
				<li class="current_page_item"><a href="repurposing.html" accesskey="2" title="">Drug repurposing</a></li>
				<li><a href="deepmind.html" accesskey="3" title="">DeepMind repurposing</a></li>
				<li><a href="hitsPublications.html" accesskey="4" title="">Hits from publications</a></li>
				<li><a href="hitsChemicalChecker.html" accesskey="5" title="">Hits from ChemChecker</a></li>
				<li><a href="all.html" accesskey="6" title="">All interactions</a></li>
			</ul>
		</div>
	</div>
	
	
	<table style="width: 100%; text-align: justify; margin-left: auto; margin-right: auto; font-size:80%" border="0" cellpadding="5" cellspacing="5" >
		<tbody>
			<tr>
				<td style="text-align: justify; vertical-align: top; width: 50%;">
					<p><b>This section</b>: We are searching the best current drugs that could be used to treat COVID-19. Drug repurposing means that a drug that is currently used for a specific condition could be effective in treating a new condition (COVID-19). Therefore, we calculated the affinity energies for the interactions between all drugs (ligands) available at <i><a href="https://www.drugbank.ca/" target="_blank">DrugBank database</a></i> (DB) and different human and SARS-CoV-2 proteins (targets). The drugs should interact with viral proteins in order to disturb the normal function in the virus multiplication or with human proteins from cell receptors or other human proteins involved in virus multiplication (the virus uses human cell proteins to multiply). 
					</p>
					
					<p><b>Hint</b>: Search for a specific drug in the table below or identify it in the dynamic plots to compare it with other drugs. You can export pictures from the plot, zoom in/out, etc. (check the tools by moving the cursor above the plot). </p>
					
				</td>
				
				<td style="text-align: justify; vertical-align: top; width: 50%;">
						
					<font color="#27AAE1">
						<p><b>Our Results</b>: 
						The first dynamic plot depicts as a box plot all the interactions of the current drugs with different protein targets (from human or virus). In addition all the datapoints are plotted to identify each interaction. The current results show that the best drugs for the ACE2 human receptor protein (PDB ID: 6CS2) are two carboxamide derivates (DB07020 and DB07833), Nilotinib (DB04868), Phthalocyanine (DB12983) and Radotinib (DB12323). The best target for interaction is 6CS2 (the area of virus contact with the ACE2 receptor protein). The second dynamic plot presents only the best 50 interactions of the current drugs grouped by target.</p>
						
						<p>The table shows the best 1548 interactions between all current drugs and different protein ligands. Targets=4, Ligands=1236, Ligand families=DB (drugs). The compound with the most negative AE value (lowest AE) has the best interaction with a specific target. All the interactions are presented as plots, using AE values for each pair of drug - protein target, with a cutoff of -8.5 kcal/mol (only strong interactions = 1559 drug - target interactions).</p>
					</font>
				</td>
			</tr>
		</tbody>
	</table>
	
	
	<!-- Including top5 multidocking visualization-->
	<div align="center">
		<table style="width:100%">
			<tr align="center">
				<th>
					<iframe src="extras/repurposing_boxplot_byTargets.html" height="500" width="600" frameborder="0" scrolling=yes seamless  ></iframe>
				</th>
				<th><iframe src="extras/repurposing_AE_LigandByTarget.html" height="500" width="600" frameborder="0" scrolling=yes seamless  ></iframe>
				</th>
			</tr>
		</table>
		
			
	</div>	
	
	<!-- Generated dynamic table tr style="text-align: center;" -->	
	<div align="center">
		<p><b>Interactions between Databank drug ligands with human and virus protein targets</b></p>
		<table table id="example" style="width:100%" class="display" style="font-family:"Courier New";>
   <thead>
    <tr style="text-align: center;">
      <th>AE</th>
      <th>Target</th>
      <th>Ligand</th>
      <th>GENERIC_NAME</th>
      <th>INCHI_KEY</th>
      <th>Note</th>
    </tr>
  </thead tyle="text-align: center;">
  <tbody>
    <tr>
      <td>-11.7</td>
      <td>6CS2</td>
      <td>DB07020</td>
      <td>N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide</td>
      <td>LMDMJDCLPIVGQD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-11.5</td>
      <td>6CS2</td>
      <td>DB04868</td>
      <td>Nilotinib</td>
      <td>HHZIURLSWUIHRB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-11.5</td>
      <td>6CS2</td>
      <td>DB07833</td>
      <td>N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide</td>
      <td>PMMLSQFPBFKLHH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-11.4</td>
      <td>6CS2</td>
      <td>DB12983</td>
      <td>Phthalocyanine</td>
      <td>IEQIEDJGQAUEQZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-11.3</td>
      <td>6CS2</td>
      <td>DB12323</td>
      <td>Radotinib</td>
      <td>DUPWHXBITIZIKZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-11.1</td>
      <td>6CS2</td>
      <td>DB03878</td>
      <td>N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide</td>
      <td>YWQVBESSYLICRX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-11.1</td>
      <td>6CS2</td>
      <td>DB07586</td>
      <td>5-(4-METHYL-BENZOYLAMINO)-BIPHENYL-3,4'-DICARBOXYLIC ACID 3-DIMETHYLAMIDE-4'-HYDROXYAMIDE</td>
      <td>DOPFUKKMSDUVTQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-11.0</td>
      <td>6CS2</td>
      <td>DB01897</td>
      <td>2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride</td>
      <td>BEIGFKLRGRRJJA-JLHYYAGUSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.9</td>
      <td>6CS2</td>
      <td>DB08450</td>
      <td>N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine</td>
      <td>HNHRWNUXTCATSG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.9</td>
      <td>6CS2</td>
      <td>DB07834</td>
      <td>N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide</td>
      <td>FOHZGCHKLPIBBX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.9</td>
      <td>6CS2</td>
      <td>DB12694</td>
      <td>CE-326597</td>
      <td>UBNMGTSDHSQBEL-PMERELPUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.8</td>
      <td>6CS2</td>
      <td>DB00210</td>
      <td>Adapalene</td>
      <td>LZCDAPDGXCYOEH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.8</td>
      <td>6CS2</td>
      <td>DB12693</td>
      <td>Ritanserin</td>
      <td>JUQLTPCYUFPYKE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.8</td>
      <td>6CS2</td>
      <td>DB14894</td>
      <td>Galicaftor</td>
      <td>QVDYQHXNAQHIKH-TZIWHRDSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.8</td>
      <td>6CS2</td>
      <td>DB14878</td>
      <td>Liafensine</td>
      <td>VCIBGDSRPUOBOG-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.8</td>
      <td>6CS2</td>
      <td>DB07307</td>
      <td>N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide</td>
      <td>GQXMJOSCBRZMKE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.7</td>
      <td>6CS2</td>
      <td>DB15327</td>
      <td>Abivertinib</td>
      <td>UOFYSRZSLXWIQB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.7</td>
      <td>6CS2</td>
      <td>DB15343</td>
      <td>HM-43239</td>
      <td>FZLSDZZNPXXBBB-KDURUIRLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.7</td>
      <td>6CS2</td>
      <td>DB12886</td>
      <td>GSK-1521498</td>
      <td>WIEDUMBCZQRGSY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.6</td>
      <td>6CS2</td>
      <td>DB12571</td>
      <td>Rimacalib</td>
      <td>MYTIJGWONQOOLC-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.6</td>
      <td>6CS2</td>
      <td>DB13095</td>
      <td>JTK-853</td>
      <td>JQLOVYLALGSISI-HXUWFJFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.6</td>
      <td>6CS2</td>
      <td>DB12784</td>
      <td>NS-018</td>
      <td>UQTPDWDAYHAZNT-AWEZNQCLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.6</td>
      <td>6CS2</td>
      <td>DB12799</td>
      <td>Laniquidar</td>
      <td>TULGGJGJQXESOO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.6</td>
      <td>6CS2</td>
      <td>DB15039</td>
      <td>ITI-214</td>
      <td>BBIPVJCGIASXJB-PKTZIBPZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.6</td>
      <td>6CS2</td>
      <td>DB07994</td>
      <td>N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE</td>
      <td>KMBPJSHPAXOXBT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.5</td>
      <td>6LZG</td>
      <td>DB11852</td>
      <td>Tegobuvir</td>
      <td>XBEQSQDCBSKCHJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.5</td>
      <td>6CS2</td>
      <td>DB12424</td>
      <td>MK-3207</td>
      <td>AZAANWYREOQRFB-SETSBSEESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.5</td>
      <td>6CS2</td>
      <td>DB03571</td>
      <td>3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-N-(3,5-Dichlorobenzyl)-Benzamide</td>
      <td>JMQTXEWNXSPEKX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.4</td>
      <td>6CS2</td>
      <td>DB08349</td>
      <td>N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide</td>
      <td>WMEYCLAVMZKZCS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.4</td>
      <td>6CS2</td>
      <td>DB08221</td>
      <td>N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE</td>
      <td>NESXBRNDMQUVNG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.4</td>
      <td>6CS2</td>
      <td>DB15036</td>
      <td>Sitravatinib</td>
      <td>WLAVZAAODLTUSW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.4</td>
      <td>6CS2</td>
      <td>DB05835</td>
      <td>NS-3728</td>
      <td>OQRAKHDEGGGWQO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.4</td>
      <td>6CS2</td>
      <td>DB01988</td>
      <td>6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine</td>
      <td>WFSFNKVFXLIZIY-MHZLTWQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.4</td>
      <td>6CS2</td>
      <td>DB08553</td>
      <td>(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime</td>
      <td>KWEFZSZCLBHIEQ-YYADALCUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.4</td>
      <td>6LZG</td>
      <td>DB14773</td>
      <td>Lifirafenib</td>
      <td>NGFFVZQXSRKHBM-FKBYEOEOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6LZG</td>
      <td>DB12154</td>
      <td>Itacitinib</td>
      <td>KTBSXLIQKWEBRB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6CS2</td>
      <td>DB06896</td>
      <td>1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide</td>
      <td>OBSFXHDOLBYWRJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6CS2</td>
      <td>DB13029</td>
      <td>MK-0873</td>
      <td>JJWKQXNHYDJXKF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6LZG</td>
      <td>DB05984</td>
      <td>RAF-265</td>
      <td>YABJJWZLRMPFSI-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6CS2</td>
      <td>DB14883</td>
      <td>Lorecivivint</td>
      <td>AQDWDWAYVBQMAM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6CS2</td>
      <td>DB13050</td>
      <td>Tirilazad</td>
      <td>RBKASMJPSJDQKY-RBFSKHHSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6LZG</td>
      <td>DB12411</td>
      <td>R-428</td>
      <td>KXMZDGSRSGHMMK-VWLOTQADSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.3</td>
      <td>6CS2</td>
      <td>DB11913</td>
      <td>LY-2090314</td>
      <td>HRJWTAWVFDCTGO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB13109</td>
      <td>PKI-179</td>
      <td>WXUUCRLKXQMWRY-OYRHEFFESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB06435</td>
      <td>Tarazepide</td>
      <td>CZPILLBHPRAPCB-AREMUKBSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB12269</td>
      <td>PF-06273340</td>
      <td>BPIWZDNVMQQBQX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB01948</td>
      <td>1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One</td>
      <td>VXIYTVJEIXMAQF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB03044</td>
      <td>1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea</td>
      <td>MVCOAUNKQVWQHZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB11772</td>
      <td>Pilaralisib</td>
      <td>QINPEPAQOBZPOF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB13874</td>
      <td>Enasidenib</td>
      <td>DYLUUSLLRIQKOE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB08883</td>
      <td>Perampanel</td>
      <td>PRMWGUBFXWROHD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB13164</td>
      <td>Olmutinib</td>
      <td>FDMQDKQUTRLUBU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB12411</td>
      <td>R-428</td>
      <td>KXMZDGSRSGHMMK-VWLOTQADSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB15401</td>
      <td>Danicopan</td>
      <td>PIBARDGJJAGJAJ-NQIIRXRSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB15437</td>
      <td>Rocacetrapib</td>
      <td>GBHPDJQHZADVAA-SOKVYYICSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB06555</td>
      <td>Siramesine</td>
      <td>XWAONOGAGZNUSF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB01691</td>
      <td>Indole Naphthyridinone</td>
      <td>VAZMNDXVXVUKFY-JXMROGBWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB04739</td>
      <td>4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE</td>
      <td>JHMBUEWQJDGKGS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB12973</td>
      <td>Serlopitant</td>
      <td>FLNYCRJBCNNHRH-OIYLJQICSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB07794</td>
      <td>5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE</td>
      <td>XVECMUKVOMUNLE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6CS2</td>
      <td>DB11896</td>
      <td>Gedatolisib</td>
      <td>DWZAEMINVBZMHQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.2</td>
      <td>6LZG</td>
      <td>DB12983</td>
      <td>Phthalocyanine</td>
      <td>IEQIEDJGQAUEQZ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB08730</td>
      <td>3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE</td>
      <td>CPFBZMFUCGHBAP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB08362</td>
      <td>N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE</td>
      <td>QVKXQLGRDOMAGC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB13371</td>
      <td>Difenpiramide</td>
      <td>PWHROYKAGRUWDQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB07665</td>
      <td>N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide</td>
      <td>STHCHQXQLDMISY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB08197</td>
      <td>(5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime</td>
      <td>KYIXUSLGFINPTC-WVFAEZDRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB11977</td>
      <td>Golvatinib</td>
      <td>UQRCJCNVNUFYDX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB11830</td>
      <td>Mocetinostat</td>
      <td>HRNLUBSXIHFDHP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB02112</td>
      <td>Zk-806450</td>
      <td>DZLGSWPXZYDHBD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB07993</td>
      <td>N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE</td>
      <td>LPQUIIHPUGDHJK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB00696</td>
      <td>Ergotamine</td>
      <td>XCGSFFUVFURLIX-VFGNJEKYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB12270</td>
      <td>Losmapimod</td>
      <td>KKYABQBFGDZVNQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB11262</td>
      <td>Bisoctrizole</td>
      <td>FQUNFJULCYSSOP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB14993</td>
      <td>Pyrotinib</td>
      <td>SADXACCFNXBCFY-IYNHSRRRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB12690</td>
      <td>LY-2584702</td>
      <td>FYXRSVDHGLUMHB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB11907</td>
      <td>Rociletinib</td>
      <td>HUFOZJXAKZVRNJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.1</td>
      <td>6CS2</td>
      <td>DB07189</td>
      <td>(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid</td>
      <td>BFZXMIUWGSTUAL-ZSOKXDGFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB11911</td>
      <td>Galunisertib</td>
      <td>IVRXNBXKWIJUQB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6LZG</td>
      <td>DB14883</td>
      <td>Lorecivivint</td>
      <td>AQDWDWAYVBQMAM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB15345</td>
      <td>GSK-945237</td>
      <td>SRICOHRDRMZREQ-MRXNPFEDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB14766</td>
      <td>Etrasimod</td>
      <td>MVGWUTBTXDYMND-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB02269</td>
      <td>[4-({[5-Benzyloxy-1-(3-Carbamimidoyl-Benzyl)-1h-Indole-2-Carbonyl]-Amino}-Methyl)-Phenyl]-Trimethyl-Ammonium</td>
      <td>UFKJQTGPBFWMGT-UHFFFAOYSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB15011</td>
      <td>Avacopan</td>
      <td>PUKBOVABABRILL-YZNIXAGQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB12042</td>
      <td>Ibodutant</td>
      <td>YQYSVMKCMIUCHY-WJOKGBTCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6LZG</td>
      <td>DB11399</td>
      <td>Dirlotapide</td>
      <td>TUOSYWCFRFNJBS-BHVANESWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB01761</td>
      <td>4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine</td>
      <td>QICPQLFMWYQJGX-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB04289</td>
      <td>Genz-10850</td>
      <td>YYMZSGIXLQPFAC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB12207</td>
      <td>Verdinexor</td>
      <td>OPAKEJZFFCECPN-XQRVVYSFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB04879</td>
      <td>Vatalanib</td>
      <td>YCOYDOIWSSHVCK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB08881</td>
      <td>Vemurafenib</td>
      <td>GPXBXXGIAQBQNI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB12547</td>
      <td>LY-2886721</td>
      <td>NIDRNVHMMDAAIK-YPMLDQLKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB08386</td>
      <td>2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline</td>
      <td>VRWJZGHUCOFGPZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB13040</td>
      <td>Gandotinib</td>
      <td>SQSZANZGUXWJEA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6LZG</td>
      <td>DB06938</td>
      <td>4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide</td>
      <td>ZJLSMLDOCGOURY-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB06717</td>
      <td>Fosaprepitant</td>
      <td>BARDROPHSZEBKC-OITMNORJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB02033</td>
      <td>N-(3-Cyclopropyl(5,6,7,8,9,10-Hexahydro-2-Oxo-2h-Cycloocta[B]Pyran-3-Yl)Methyl)Phenylbenzensulfonamide</td>
      <td>GDRNWAKVNIROCG-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB11651</td>
      <td>Dactolisib</td>
      <td>JOGKUKXHTYWRGZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-10.0</td>
      <td>6CS2</td>
      <td>DB12432</td>
      <td>CC-401</td>
      <td>XDJCLCLBSGGNKS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB05984</td>
      <td>RAF-265</td>
      <td>YABJJWZLRMPFSI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB07811</td>
      <td>N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide</td>
      <td>UBVTVSINEVHYSY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB15307</td>
      <td>Atabecestat</td>
      <td>VLLFGVHGKLDDLW-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB03632</td>
      <td>Argifin</td>
      <td>UHBHXSDKGLPPGO-HTDHLNIYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB03276</td>
      <td>4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid</td>
      <td>RHYFMOCFCFUTNH-GZNVFMSSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB08351</td>
      <td>N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide</td>
      <td>MNEXDVSJIUQQRH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6LZG</td>
      <td>DB11977</td>
      <td>Golvatinib</td>
      <td>UQRCJCNVNUFYDX-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB11942</td>
      <td>Selinexor</td>
      <td>DEVSOMFAQLZNKR-RJRFIUFISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB14029</td>
      <td>Furafylline</td>
      <td>HMZQULPVMKITSP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB08901</td>
      <td>Ponatinib</td>
      <td>PHXJVRSECIGDHY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB06962</td>
      <td>(5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone</td>
      <td>YKTUSHSSKIWDRY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB15414</td>
      <td>CM-4307</td>
      <td>MLDQJTXFUGDVEO-FIBGUPNXSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB04408</td>
      <td>Ncs-Chromophore</td>
      <td>QZGIWPZCWHMVQL-UIYAJPBUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB08010</td>
      <td>(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime</td>
      <td>DDHASJXGNUWZTM-ZLEWNXFRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB14773</td>
      <td>Lifirafenib</td>
      <td>NGFFVZQXSRKHBM-FKBYEOEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6LZG</td>
      <td>DB07833</td>
      <td>N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide</td>
      <td>PMMLSQFPBFKLHH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6LZG</td>
      <td>DB05075</td>
      <td>TG-100801</td>
      <td>JMGXJHWTVBGOKG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB11816</td>
      <td>Omecamtiv Mecarbil</td>
      <td>RFUBTTPMWSKEIW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB11852</td>
      <td>Tegobuvir</td>
      <td>XBEQSQDCBSKCHJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB04708</td>
      <td>(S)-TETRAHYDROFURAN-3-YL (2S,3S)-4-((S)-4-((1R,3R)-3-(2-AMINO-2-OXOETHYL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-BENZYL-3-OXO-2,3-DIHYDRO-1H-PYRROL-2-YL)-3-HYDROXY-1-PHENYLBUTAN-2-YLCARBAMATE</td>
      <td>SYNSHNDQFWMLJW-YZGRCXSVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB15233</td>
      <td>Avapritinib</td>
      <td>DWYRIWUZIJHQKQ-SANMLTNESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB11399</td>
      <td>Dirlotapide</td>
      <td>TUOSYWCFRFNJBS-BHVANESWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB07390</td>
      <td>2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE</td>
      <td>RKWXKADYTDWZIJ-VIFPVBQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB08034</td>
      <td>(E)-3,4-DIHYDROXY-N'-[(2-METHOXYNAPHTHALEN-1-YL)METHYLENE]BENZOHYDRAZIDE</td>
      <td>TVOPERZEGKBKAY-RGVLZGJSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB06486</td>
      <td>Enzastaurin</td>
      <td>AXRCEOKUDYDWLF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6LZG</td>
      <td>DB04868</td>
      <td>Nilotinib</td>
      <td>HHZIURLSWUIHRB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB15003</td>
      <td>PF-06700841</td>
      <td>BUWBRTXGQRBBHG-MJBXVCDLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB04016</td>
      <td>2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid</td>
      <td>XUJQPDQURBZEGJ-KXQOOQHDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB09280</td>
      <td>Lumacaftor</td>
      <td>UFSKUSARDNFIRC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6LZG</td>
      <td>DB12323</td>
      <td>Radotinib</td>
      <td>DUPWHXBITIZIKZ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB15297</td>
      <td>Petesicatib</td>
      <td>KXAAIORSMACJSI-AEFFLSMTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB06626</td>
      <td>Axitinib</td>
      <td>RITAVMQDGBJQJZ-FMIVXFBMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB09291</td>
      <td>Rolapitant</td>
      <td>FIVSJYGQAIEMOC-ZGNKEGEESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.9</td>
      <td>6CS2</td>
      <td>DB12368</td>
      <td>AZD-3839</td>
      <td>MRXBCEQZNKUUIP-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB15391</td>
      <td>Elenbecestat</td>
      <td>AACUJFVOHGRMTR-DPXNYUHVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB06834</td>
      <td>N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide</td>
      <td>XZRYCTLOGNCQDG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB05454</td>
      <td>Paliroden</td>
      <td>CNEWKIDCGDXBDE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB08036</td>
      <td>6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one</td>
      <td>MEXUTNIFSHFQRG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB06925</td>
      <td>3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE</td>
      <td>YEIASMOUYNOXGA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB06248</td>
      <td>Amelubant</td>
      <td>SBVYURPQULDJTI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB00619</td>
      <td>Imatinib</td>
      <td>KTUFNOKKBVMGRW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB15009</td>
      <td>PF-04937319</td>
      <td>MASKQITXHVYVFL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB04727</td>
      <td>N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA</td>
      <td>FGZIONRFHVNRJB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB15191</td>
      <td>MAX-40279</td>
      <td>AVIOBQFPAGEICQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB14845</td>
      <td>Filgotinib</td>
      <td>RIJLVEAXPNLDTC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB11851</td>
      <td>Bafetinib</td>
      <td>ZGBAJMQHJDFTQJ-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB00320</td>
      <td>Dihydroergotamine</td>
      <td>LUZRJRNZXALNLM-JGRZULCMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB03777</td>
      <td>Rbt205 Inhibitor</td>
      <td>QMGUOJYZJKLOLH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB12394</td>
      <td>Eleclazine</td>
      <td>YNUAEEJQYHYLMS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB06938</td>
      <td>4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide</td>
      <td>ZJLSMLDOCGOURY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB12341</td>
      <td>LY-2456302</td>
      <td>ZHPMYDSXGRRERG-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB08454</td>
      <td>N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE</td>
      <td>JYCUVOXSZBECAY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB12673</td>
      <td>ATX-914</td>
      <td>ALANRBCCCQEPFZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB07321</td>
      <td>2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE</td>
      <td>KOKQLKWXOFRTHE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB14916</td>
      <td>Selonsertib</td>
      <td>YIDDLAAKOYYGJG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB08068</td>
      <td>N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-</td>
      <td>YQJVDUKATDECHF-ICSRJNTNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB11652</td>
      <td>Tucatinib</td>
      <td>SDEAXTCZPQIFQM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB08907</td>
      <td>Canagliflozin</td>
      <td>XTNGUQKDFGDXSJ-ZXGKGEBGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB14943</td>
      <td>LGH-447</td>
      <td>VRQXRVAKPDCRCI-ZNMIVQPWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6LZG</td>
      <td>DB14935</td>
      <td>Serabelisib</td>
      <td>BLGWHBSBBJNKJO-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB08058</td>
      <td>4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one</td>
      <td>HGEPGGJUGUMFHT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6LZG</td>
      <td>DB03231</td>
      <td>3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide</td>
      <td>IXDQOBDHBWEZOH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.8</td>
      <td>6CS2</td>
      <td>DB01100</td>
      <td>Pimozide</td>
      <td>YVUQSNJEYSNKRX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB13520</td>
      <td>Metergoline</td>
      <td>WZHJKEUHNJHDLS-QTGUNEKASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB04842</td>
      <td>Fluspirilene</td>
      <td>QOYHHIBFXOOADH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB13005</td>
      <td>Rebastinib</td>
      <td>WVXNSAVVKYZVOE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB12320</td>
      <td>Palovarotene</td>
      <td>YTFHCXIPDIHOIA-DHZHZOJOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB08091</td>
      <td>3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE</td>
      <td>HIUFYIOMUILESI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6LZG</td>
      <td>DB14785</td>
      <td>Fenebrutinib</td>
      <td>WNEODWDFDXWOLU-QHCPKHFHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6LZG</td>
      <td>DB15399</td>
      <td>BMS-754807</td>
      <td>LQVXSNNAFNGRAH-QHCPKHFHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB15034</td>
      <td>PRI-724</td>
      <td>VHOZWHQPEJGPCC-AZXNYEMZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB12561</td>
      <td>WNT-974</td>
      <td>XXYGTCZJJLTAGH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB11870</td>
      <td>RG-4733</td>
      <td>OJPLJFIFUQPSJR-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB02551</td>
      <td>6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</td>
      <td>LVNMYQLXKMSQTG-AWEZNQCLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB03957</td>
      <td>SP2456</td>
      <td>SSSXBBASYYVGCI-HSZRJFAPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6LZG</td>
      <td>DB14850</td>
      <td>Deleobuvir</td>
      <td>BMAIGAHXAJEULY-UKTHLTGXSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB07382</td>
      <td>N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine</td>
      <td>WJNBSTLIALIIEW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB14785</td>
      <td>Fenebrutinib</td>
      <td>WNEODWDFDXWOLU-QHCPKHFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB08384</td>
      <td>2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline</td>
      <td>RQDDHVVAAJVVKM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB03082</td>
      <td>6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide</td>
      <td>CSWQJKHBMACTGB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB06882</td>
      <td>1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea</td>
      <td>HJWMLCDGRWWLAQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB07514</td>
      <td>3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one</td>
      <td>LHLGUOHREUTYTO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB02741</td>
      <td>CD564</td>
      <td>RWYREGSYPCNZTL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB08358</td>
      <td>2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE</td>
      <td>OWFLADWRSCINST-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6LZG</td>
      <td>DB03276</td>
      <td>4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid</td>
      <td>RHYFMOCFCFUTNH-GZNVFMSSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB11923</td>
      <td>Decoglurant</td>
      <td>DMJHZVARRXJSEG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB07508</td>
      <td>4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE</td>
      <td>MEUAVGJWGDPTLF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6LZG</td>
      <td>DB11618</td>
      <td>Zorubicin</td>
      <td>FBTUMDXHSRTGRV-BJISBDEGSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB01879</td>
      <td>(S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid</td>
      <td>JOAALZBSMWLOPQ-LJAQVGFWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB12297</td>
      <td>GLPG-0187</td>
      <td>CXHCNOMGODVIKB-VWLOTQADSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6LZG</td>
      <td>DB12424</td>
      <td>MK-3207</td>
      <td>AZAANWYREOQRFB-SETSBSEESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB07457</td>
      <td>3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE</td>
      <td>APYXQTXFRIDSGE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB09183</td>
      <td>Dasabuvir</td>
      <td>NBRBXGKOEOGLOI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.7</td>
      <td>6CS2</td>
      <td>DB04373</td>
      <td>4-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide</td>
      <td>WQUBEIMCFHCJCO-AWCRTANDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB04881</td>
      <td>Elacridar</td>
      <td>OSFCMRGOZNQUSW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB14895</td>
      <td>Vibegron</td>
      <td>DJXRIQMCROIRCZ-XOEOCAAJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB15189</td>
      <td>Birabresib</td>
      <td>GNMUEVRJHCWKTO-FQEVSTJZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB15110</td>
      <td>Onvansertib</td>
      <td>QHLVBNKYJGBCQJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6LZG</td>
      <td>DB15308</td>
      <td>Ridinilazole</td>
      <td>UHQFBTAJFNVZIV-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6LZG</td>
      <td>DB07789</td>
      <td>1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea</td>
      <td>KNTGXMNWVXZIMW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6LZG</td>
      <td>DB15328</td>
      <td>Ubrogepant</td>
      <td>DDOOFTLHJSMHLN-ZQHRPCGSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB11521</td>
      <td>Imidocarb</td>
      <td>SCEVFJUWLLRELN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB15291</td>
      <td>BMS-986142</td>
      <td>ZRYMMWAJAFUANM-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB07743</td>
      <td>S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE</td>
      <td>VNGWUVBXUIDQTK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB07789</td>
      <td>1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea</td>
      <td>KNTGXMNWVXZIMW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB07837</td>
      <td>[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid</td>
      <td>SWXKLXXVFMYMDP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB11841</td>
      <td>Entinostat</td>
      <td>INVTYAOGFAGBOE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB03331</td>
      <td>N-Naphthalen-1-Ylmethyl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</td>
      <td>OARVXDFNTLYMCJ-JVUUKAHWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB06334</td>
      <td>Tucidinostat</td>
      <td>SZMJVTADHFNAIS-BJMVGYQFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB01419</td>
      <td>Antrafenine</td>
      <td>NWGGKKGAFZIVBJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB12302</td>
      <td>CP-724714</td>
      <td>LLVZBTWPGQVVLW-SNAWJCMRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB01411</td>
      <td>Pranlukast</td>
      <td>NBQKINXMPLXUET-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB14860</td>
      <td>Ensartinib</td>
      <td>GLYMPHUVMRFTFV-QLFBSQMISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB13042</td>
      <td>Fenoverine</td>
      <td>UBAJTZKNDCEGKL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB06144</td>
      <td>Sertindole</td>
      <td>GZKLJWGUPQBVJQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB08242</td>
      <td>N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide</td>
      <td>OYTBZXSFNNAVKU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB12978</td>
      <td>Pexidartinib</td>
      <td>JGWRKYUXBBNENE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB12580</td>
      <td>Tradipitant</td>
      <td>CAVRKWRKTNINFF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB12899</td>
      <td>TT-301</td>
      <td>ZPJGUEPHFXPAQF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6LZG</td>
      <td>DB01897</td>
      <td>2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride</td>
      <td>BEIGFKLRGRRJJA-JLHYYAGUSA-O</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB06844</td>
      <td>4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE</td>
      <td>MBXKBJLIESPLIK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6LZG</td>
      <td>DB12694</td>
      <td>CE-326597</td>
      <td>UBNMGTSDHSQBEL-PMERELPUSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6LZG</td>
      <td>DB06896</td>
      <td>1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide</td>
      <td>OBSFXHDOLBYWRJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB08299</td>
      <td>4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid</td>
      <td>QTNUWEKKZHSUQO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB13953</td>
      <td>Estradiol benzoate</td>
      <td>UYIFTLBWAOGQBI-BZDYCCQFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB07181</td>
      <td>4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide</td>
      <td>JYKFWUXBFJJDTP-HXUWFJFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB12012</td>
      <td>PF-04457845</td>
      <td>BATCTBJIJJEPHM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB09074</td>
      <td>Olaparib</td>
      <td>FDLYAMZZIXQODN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB14790</td>
      <td>BPN-14770</td>
      <td>KRRGWHSEDYQKDQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6LZG</td>
      <td>DB11913</td>
      <td>LY-2090314</td>
      <td>HRJWTAWVFDCTGO-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB07548</td>
      <td>2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE</td>
      <td>JXHWVKOKYDAROD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB07545</td>
      <td>N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE</td>
      <td>RDTDWGQDFJPTPD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB04285</td>
      <td>{4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid</td>
      <td>GBLDYRVJENYQNH-AGLOJYHOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB11904</td>
      <td>Flumatinib</td>
      <td>BJCJYEYYYGBROF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.6</td>
      <td>6CS2</td>
      <td>DB11986</td>
      <td>Entrectinib</td>
      <td>HAYYBYPASCDWEQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB02354</td>
      <td>4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine</td>
      <td>IRKPNOLLMNHSOU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB15151</td>
      <td>RO-6870810</td>
      <td>PKQXLRYFPSZKDU-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB14889</td>
      <td>Derazantinib</td>
      <td>KPJDVVCDVBFRMU-AREMUKBSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB07800</td>
      <td>N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE</td>
      <td>MIJGLXFQYBTIFY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB12895</td>
      <td>TD-139</td>
      <td>YGIDGBAHDZEYMT-MQFIMZJJSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB12886</td>
      <td>GSK-1521498</td>
      <td>WIEDUMBCZQRGSY-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB15183</td>
      <td>Fosmanogepix</td>
      <td>JQONJQKKVAHONF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB14792</td>
      <td>AZD-5991</td>
      <td>KBQCEQAXHPIRTF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB06963</td>
      <td>3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide</td>
      <td>ZFGCLYUGFRNYFE-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB12690</td>
      <td>LY-2584702</td>
      <td>FYXRSVDHGLUMHB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB11863</td>
      <td>Alvelestat</td>
      <td>QNQZWEGMKJBHEM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB11791</td>
      <td>Capmatinib</td>
      <td>LIOLIMKSCNQPLV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB12799</td>
      <td>Laniquidar</td>
      <td>TULGGJGJQXESOO-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB06897</td>
      <td>3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol</td>
      <td>MMGKIHLBFPJYJL-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB12743</td>
      <td>Z-160</td>
      <td>VCPMZDWBEWTGNW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB06933</td>
      <td>N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide</td>
      <td>GJTCKUKIFXWJKG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB12760</td>
      <td>GW-493838</td>
      <td>ZQYJPMPXQLNTPQ-QCUYGVNKSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB15145</td>
      <td>Ziresovir</td>
      <td>GAAICKUTDBZCMT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB05713</td>
      <td>LY-517717</td>
      <td>VYNKVNDKAOGAAQ-RUZDIDTESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB12588</td>
      <td>AZD-1480</td>
      <td>PDOQBOJDRPLBQU-QMMMGPOBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB11904</td>
      <td>Flumatinib</td>
      <td>BJCJYEYYYGBROF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB07245</td>
      <td>6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE</td>
      <td>AEVBKBAFFJKFJZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB13454</td>
      <td>Nicomorphine</td>
      <td>HNDXBGYRMHRUFN-CIVUWBIHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB12369</td>
      <td>Sotrastaurin</td>
      <td>OAVGBZOFDPFGPJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB07729</td>
      <td>3-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzamide</td>
      <td>GAKOBKPDJJGRIL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB00568</td>
      <td>Cinnarizine</td>
      <td>DERZBLKQOCDDDZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB06393</td>
      <td>Xaliproden</td>
      <td>WJJYZXPHLSLMGE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB07152</td>
      <td>N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide</td>
      <td>TYPILNNEZPSNTI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB12412</td>
      <td>Gemigliptin</td>
      <td>ZWPRRQZNBDYKLH-VIFPVBQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB04852</td>
      <td>Implitapide</td>
      <td>AMNXBQPRODZJQR-DITALETJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB13095</td>
      <td>JTK-853</td>
      <td>JQLOVYLALGSISI-HXUWFJFHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB13059</td>
      <td>PF-03814735</td>
      <td>RYYNGWLOYLRZLK-RBUKOAKNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB11697</td>
      <td>Pacritinib</td>
      <td>HWXVIOGONBBTBY-ONEGZZNKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB14935</td>
      <td>Serabelisib</td>
      <td>BLGWHBSBBJNKJO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB13024</td>
      <td>MK-8245</td>
      <td>UJEAABFSXKCSGI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB12200</td>
      <td>Tivantinib</td>
      <td>UCEQXRCJXIVODC-PMACEKPBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB12044</td>
      <td>MK-0893</td>
      <td>DNTVJEMGHBIUMW-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB13014</td>
      <td>Hypericin</td>
      <td>BTXNYTINYBABQR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB11891</td>
      <td>CUDC-907</td>
      <td>JOWXJLIFIIOYMS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB12673</td>
      <td>ATX-914</td>
      <td>ALANRBCCCQEPFZ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB14840</td>
      <td>Ripretinib</td>
      <td>CEFJVGZHQAGLHS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB15308</td>
      <td>Ridinilazole</td>
      <td>UHQFBTAJFNVZIV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB08584</td>
      <td>6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline</td>
      <td>BCZUAADEACICHN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB03591</td>
      <td>RU82209</td>
      <td>LVZDQVATAQEMCX-NSOVKSMOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB07967</td>
      <td>9-CYCLOPENTYL-6-[2-(3-IMIDAZOL-1-YL-PROPOXY)-PHENYLAMINO]-9H-PURINE-2-CARBONITRILE</td>
      <td>JJNKDTWKWYLERH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB08901</td>
      <td>Ponatinib</td>
      <td>PHXJVRSECIGDHY-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB09030</td>
      <td>Vorapaxar</td>
      <td>ZBGXUVOIWDMMJE-QHNZEKIYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB15399</td>
      <td>BMS-754807</td>
      <td>LQVXSNNAFNGRAH-QHCPKHFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB07970</td>
      <td>5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide</td>
      <td>SAAYRHKJHDIDPH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB15382</td>
      <td>SAR-125844</td>
      <td>ODIUNTQOXRXOIV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB08512</td>
      <td>6-amino-2-[(1-naphthylmethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one</td>
      <td>MCEZMMDIEXECTI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB00320</td>
      <td>Dihydroergotamine</td>
      <td>LUZRJRNZXALNLM-JGRZULCMSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB00762</td>
      <td>Irinotecan</td>
      <td>UWKQSNNFCGGAFS-XIFFEERXSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB08446</td>
      <td>3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile</td>
      <td>OHQMEDBYNUAVNE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB08738</td>
      <td>1-{3-oxo-3-[(2S)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1H)-one</td>
      <td>KWCKZIJGKMCYCI-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB15358</td>
      <td>JNJ-54175446</td>
      <td>CWFVVQFVGMFTBD-SECBINFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB07966</td>
      <td>[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile</td>
      <td>NVMCVWOODOWOLT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6LZG</td>
      <td>DB02555</td>
      <td>SP4160</td>
      <td>VCXMTWSYQSVWRK-AREMUKBSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.5</td>
      <td>6CS2</td>
      <td>DB08387</td>
      <td>2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline</td>
      <td>AZEXWHKOMMASPA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB15085</td>
      <td>Fulacimstat</td>
      <td>JDARDSVOVYVQST-MRXNPFEDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB12318</td>
      <td>BMS-599626</td>
      <td>LUJZZYWHBDHDQX-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07220</td>
      <td>N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE</td>
      <td>ZXYIRNXOAJYLCU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB11704</td>
      <td>Adomeglivant</td>
      <td>FASLTMSUPQDLIB-MHZLTWQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB06494</td>
      <td>Sufugolix</td>
      <td>UCQSBGOFELXYIN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07229</td>
      <td>3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE</td>
      <td>MINVOLKUPZPDNX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB13345</td>
      <td>Dihydroergocristine</td>
      <td>DEQITUUQPICUMR-HJPBWRTMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB01411</td>
      <td>Pranlukast</td>
      <td>NBQKINXMPLXUET-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB15310</td>
      <td>Vactosertib</td>
      <td>FJCDSQATIJKQKA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB13556</td>
      <td>Sulfamazone</td>
      <td>BGLHAKAJGYLSOX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB15105</td>
      <td>PF-06751979</td>
      <td>ZLZUHACSRMOLLV-RAALSFIWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB08064</td>
      <td>N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA</td>
      <td>NTMADESEDXKNFZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB12186</td>
      <td>SRT-2104</td>
      <td>LAMQVIQMVKWXOC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB11799</td>
      <td>Bictegravir</td>
      <td>SOLUWJRYJLAZCX-LYOVBCGYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB04888</td>
      <td>Bifeprunox</td>
      <td>CYGODHVAJQTCBG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB14989</td>
      <td>Umbralisib</td>
      <td>IUVCFHHAEHNCFT-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB11822</td>
      <td>TMC-647055</td>
      <td>UOBYJVFBFSLCTQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB04495</td>
      <td>RU81843</td>
      <td>GGPXNASQNUOIPB-NSOVKSMOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB04591</td>
      <td>N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE</td>
      <td>VYJOAYZRCNHDNG-GOSISDBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB15382</td>
      <td>SAR-125844</td>
      <td>ODIUNTQOXRXOIV-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB06916</td>
      <td>N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE</td>
      <td>LBCGUKCXRVUULK-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB00734</td>
      <td>Risperidone</td>
      <td>RAPZEAPATHNIPO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB15448</td>
      <td>Acumapimod</td>
      <td>VGUSQKZDZHAAEE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB05611</td>
      <td>Apilimod</td>
      <td>HSKAZIJJKRAJAV-KOEQRZSOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07855</td>
      <td>(S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE</td>
      <td>CWHMAWBXRCDOEB-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB11663</td>
      <td>Pictilisib</td>
      <td>LHNIIDJUOCFXAP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07333</td>
      <td>N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE</td>
      <td>KRGKAARWVPUWSY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB13791</td>
      <td>Penfluridol</td>
      <td>MDLAAYDRRZXJIF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB11734</td>
      <td>Fedovapagon</td>
      <td>RUOLFWZIFNQQGH-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB09295</td>
      <td>Talniflumate</td>
      <td>ANMLJLFWUCQGKZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB12760</td>
      <td>GW-493838</td>
      <td>ZQYJPMPXQLNTPQ-QCUYGVNKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB08124</td>
      <td>3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE</td>
      <td>FTQYGMLRLRXBPT-IDUWFGFVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07000</td>
      <td>N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide</td>
      <td>ILXJWLWSYAWJKZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07909</td>
      <td>(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL</td>
      <td>OBWILOKKNDYPLX-HBMCJLEFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB12960</td>
      <td>INCB-9471</td>
      <td>ZMCJFJZOSKEMOM-DNKZPPIMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB06997</td>
      <td>2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide</td>
      <td>BMPOCDJEXAXXEZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB07020</td>
      <td>N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide</td>
      <td>LMDMJDCLPIVGQD-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB03642</td>
      <td>Benzofuran-2-Carboxylic Acid {(S)-3-Methyl-1-[3-Oxo-1-(Pyridin-2-Ylsulfonyl)Azepan-4-Ylcarbamoyl]Butyl}Amide</td>
      <td>VBPPNJCVXGAZDD-PMACEKPBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB12897</td>
      <td>MK-7622</td>
      <td>JUVQLZBJFOGEEO-GOTSBHOMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07041</td>
      <td>N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide</td>
      <td>FDJWFDQRPKKBFA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB12892</td>
      <td>MGB-BP-3</td>
      <td>OEKXCVYZBVOWBR-BQYQJAHWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB13005</td>
      <td>Rebastinib</td>
      <td>WVXNSAVVKYZVOE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB12535</td>
      <td>AC-430</td>
      <td>DCRWIATZWHLIPN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB03213</td>
      <td>Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone</td>
      <td>VVVXDHROXQUONB-UHFFFAOYSA-P</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB06959</td>
      <td>(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine</td>
      <td>BUCZDJYEOAQTHL-KEKNWZKVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07064</td>
      <td>(4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE</td>
      <td>HPVCRUIDFODATB-LJQANCHMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB11263</td>
      <td>Polydatin</td>
      <td>HSTZMXCBWJGKHG-CUYWLFDKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB01876</td>
      <td>Bis(5-Amidino-2-Benzimidazolyl)Methanone</td>
      <td>VVVXDHROXQUONB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB12817</td>
      <td>Zoliflodacin</td>
      <td>ZSWMIFNWDQEXDT-ZESJGQACSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6LZG</td>
      <td>DB13050</td>
      <td>Tirilazad</td>
      <td>RBKASMJPSJDQKY-RBFSKHHSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB13113</td>
      <td>JNJ-38877605</td>
      <td>JRWCBEOAFGHNNU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB00872</td>
      <td>Conivaptan</td>
      <td>IKENVDNFQMCRTR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07141</td>
      <td>5-[(3R)-3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine</td>
      <td>QVXYJVHNRPNRJL-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB02651</td>
      <td>{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)</td>
      <td>BTAGTGWPDROBMG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB12457</td>
      <td>Rimegepant</td>
      <td>KRNAOFGYEFKHPB-ANJVHQHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.4</td>
      <td>6CS2</td>
      <td>DB07175</td>
      <td>N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide</td>
      <td>CXQRKICWSCAUGW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB11965</td>
      <td>SJG-136</td>
      <td>RWZVMMQNDHPRQD-SFTDATJTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB15310</td>
      <td>Vactosertib</td>
      <td>FJCDSQATIJKQKA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB05553</td>
      <td>Regrelor</td>
      <td>NXHAXEBZOXCDKD-XIXRRVGJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB08445</td>
      <td>(3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE</td>
      <td>IFKWHPAWYJARQJ-DYVFJYSZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB15442</td>
      <td>Trilaciclib</td>
      <td>PDGKHKMBHVFCMG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB02336</td>
      <td>RU83876</td>
      <td>WCMLXBUNHNAMNH-UIOOFZCWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB14703</td>
      <td>Dexamethasone metasulfobenzoate</td>
      <td>TWQWRHIQRAZHPR-XNXCGYEVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB14894</td>
      <td>Galicaftor</td>
      <td>QVDYQHXNAQHIKH-TZIWHRDSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB03231</td>
      <td>3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide</td>
      <td>IXDQOBDHBWEZOH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB15396</td>
      <td>PF-114</td>
      <td>SLIVDYMORZGPLW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB11819</td>
      <td>ASP-4058</td>
      <td>NJNXCJPSMWKXHO-VIFPVBQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB07605</td>
      <td>2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE</td>
      <td>DHDQMXPAANQKDC-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06833</td>
      <td>1-CYCLOHEXYL-N-{[1-(4-METHYLPHENYL)-1H-INDOL-3-YL]METHYL}METHANAMINE</td>
      <td>MMIJMYOYKAKQPN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB14792</td>
      <td>AZD-5991</td>
      <td>KBQCEQAXHPIRTF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB08354</td>
      <td>2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE</td>
      <td>QCVULERVJOYHCP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB14810</td>
      <td>AZD-1656</td>
      <td>FJEJHJINOKKDCW-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07519</td>
      <td>(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one</td>
      <td>VDFBMQAUECXNKR-OAQYLSRUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB03712</td>
      <td>RU85053</td>
      <td>CEKLBQMULVLLTD-VMPREFPWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB08450</td>
      <td>N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine</td>
      <td>HNHRWNUXTCATSG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB11851</td>
      <td>Bafetinib</td>
      <td>ZGBAJMQHJDFTQJ-DEOSSOPVSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07991</td>
      <td>N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE</td>
      <td>APLJSSOXDWUNGV-GOSISDBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB00737</td>
      <td>Meclizine</td>
      <td>OCJYIGYOJCODJL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06558</td>
      <td>Tezosentan</td>
      <td>TUYWTLTWNJOZNY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB04215</td>
      <td>CRA_9076</td>
      <td>BVTBOJXEAPSOEB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB08710</td>
      <td>(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-2-{[(S)-(4-FLUOROPHENYL)(1H-TETRAZOL-5-YL)METHYL]AMINO}-1,3-THIAZOL-4(5H)-ONE</td>
      <td>BKZOQCGDCHOGOQ-MZLJFPOFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB01410</td>
      <td>Ciclesonide</td>
      <td>LUKZNWIVRBCLON-GXOBDPJESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06521</td>
      <td>Ertiprotafib</td>
      <td>FONCZICQWCUXEB-RUZDIDTESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB08708</td>
      <td>N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine</td>
      <td>XYYDXQCAYXOGQT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB08707</td>
      <td>4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine</td>
      <td>AQVFETGXIRKVAQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB00471</td>
      <td>Montelukast</td>
      <td>UCHDWCPVSPXUMX-TZIWLTJVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06454</td>
      <td>Sarizotan</td>
      <td>HKFMQJUJWSFOLY-OAQYLSRUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB08221</td>
      <td>N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE</td>
      <td>NESXBRNDMQUVNG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB08683</td>
      <td>REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE</td>
      <td>OTPNDVKVEAIXTI-IYBDPMFKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07076</td>
      <td>6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE</td>
      <td>FWTQOPWAMQXIMI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB13053</td>
      <td>CP-195543</td>
      <td>NZQDWKCNBOELAI-KSFYIVLOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06638</td>
      <td>Quarfloxin</td>
      <td>WOQIDNWTQOYDLF-CGAIIQECSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB12247</td>
      <td>AZD-4547</td>
      <td>VRQMAABPASPXMW-HDICACEKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB12228</td>
      <td>Telcagepant</td>
      <td>CGDZXLJGHVKVIE-DNVCBOLYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB00991</td>
      <td>Oxaprozin</td>
      <td>OFPXSFXSNFPTHF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06314</td>
      <td>SGX-523</td>
      <td>BCZUAADEACICHN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB12154</td>
      <td>Itacitinib</td>
      <td>KTBSXLIQKWEBRB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB01067</td>
      <td>Glipizide</td>
      <td>ZJJXGWJIGJFDTL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB02226</td>
      <td>3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium</td>
      <td>NAARZDJZGYBXKL-UHFFFAOYSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB01705</td>
      <td>Bis(5-Amidino-Benzimidazolyl)Methane</td>
      <td>QZKOOEFIMWKZPK-UHFFFAOYSA-Q</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB04154</td>
      <td>N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide</td>
      <td>ALBWBHNFOJJMCV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06163</td>
      <td>Plevitrexed</td>
      <td>IEJSCSAMMLUINT-NRFANRHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB01199</td>
      <td>Tubocurarine</td>
      <td>JFJZZMVDLULRGK-URLMMPGGSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB01678</td>
      <td>RU84687</td>
      <td>SAFPHFWYRLLBFO-NSOVKSMOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07362</td>
      <td>1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea</td>
      <td>UOLCZAFAGDOUFX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07326</td>
      <td>6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide</td>
      <td>FEGRQUWSKADGSP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB06240</td>
      <td>Tariquidar</td>
      <td>LGGHDPFKSSRQNS-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06240</td>
      <td>Tariquidar</td>
      <td>LGGHDPFKSSRQNS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB08827</td>
      <td>Lomitapide</td>
      <td>MBBCVAKAJPKAKM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB06677</td>
      <td>Clazosentan</td>
      <td>LFWCJABOXHSRGC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB12138</td>
      <td>PF-03715455</td>
      <td>VGEXRDWWPSGZDH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB12120</td>
      <td>Avoralstat</td>
      <td>TUWMKPVJGGWGNL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07404</td>
      <td>(1-HYDROXY-1-PHOSPHONO-2-[1,1';3',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID</td>
      <td>YXQQNSYZOQHKHD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07845</td>
      <td>2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide</td>
      <td>VGYXXQRDIVRILX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB11526</td>
      <td>Masitinib</td>
      <td>WJEOLQLKVOPQFV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB11691</td>
      <td>Naldemedine</td>
      <td>AXQACEQYCPKDMV-RZAWKFBISA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB11614</td>
      <td>Rupatadine</td>
      <td>WUZYKBABMWJHDL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB09195</td>
      <td>Lorpiprazole</td>
      <td>BNRMWKUVWLKDQJ-YJBOKZPZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07969</td>
      <td>3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol</td>
      <td>QNCYYRHIUFGGJX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB15137</td>
      <td>VK-2809</td>
      <td>LGGPZDRLTDGYSQ-JADSYQMUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6LZG</td>
      <td>DB15035</td>
      <td>Zanubrutinib</td>
      <td>RNOAOAWBMHREKO-QFIPXVFZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB04760</td>
      <td>PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(4-FLUORO-3-METHYL-BENZYLAMIDE)</td>
      <td>PYFRREJCFXFNRR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB15046</td>
      <td>LY-2881835</td>
      <td>FHRWHNJJQGSCQC-LJAQVGFWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB15068</td>
      <td>Agerafenib</td>
      <td>DKNUPRMJNUQNHR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB07835</td>
      <td>N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide</td>
      <td>BOPSUAHGQHFKGG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB15173</td>
      <td>JNJ-42165279</td>
      <td>YWGYNGCRVZLMCS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB04703</td>
      <td>Hesperidin</td>
      <td>QUQPHWDTPGMPEX-QJBIFVCTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.3</td>
      <td>6CS2</td>
      <td>DB14946</td>
      <td>PCO-371</td>
      <td>LDZJFVOUPUFOHX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB12635</td>
      <td>Aleplasinin</td>
      <td>HSXLMAFNWCSZGP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB06817</td>
      <td>Raltegravir</td>
      <td>CZFFBEXEKNGXKS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB14017</td>
      <td>H3B-8800</td>
      <td>YOIQWBAHJZGRFW-WVRLKXNASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB12044</td>
      <td>MK-0893</td>
      <td>DNTVJEMGHBIUMW-IBGZPJMESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB11614</td>
      <td>Rupatadine</td>
      <td>WUZYKBABMWJHDL-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB13061</td>
      <td>MLN8054</td>
      <td>HHFBDROWDBDFBR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB15257</td>
      <td>Milademetan</td>
      <td>RYAYYVTWKAOAJF-QISPRATLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB08006</td>
      <td>N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine</td>
      <td>OXYDLVAOXASTMW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB07117</td>
      <td>5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE</td>
      <td>FMKQJGOROFNCGM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB12649</td>
      <td>Ibipinabant</td>
      <td>AXJQVVLKUYCICH-OAQYLSRUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB11745</td>
      <td>Otenabant</td>
      <td>UNAZAADNBYXMIV-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB08044</td>
      <td>ABT-341</td>
      <td>NVVSPGQEXMJZIR-BMIGLBTASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB15190</td>
      <td>GLPG-0259</td>
      <td>YBFGSJUVEOYPIS-OALUTQOASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB13093</td>
      <td>TAK-593</td>
      <td>DZFZXPPHBWCXPQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB08539</td>
      <td>3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>CCDIUVLNHCGSMH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB14770</td>
      <td>Lanraplenib</td>
      <td>XCIGZBVOUQVIPI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB15033</td>
      <td>Flortaucipir</td>
      <td>GETAAWDSFUCLBS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB12180</td>
      <td>Apitolisib</td>
      <td>YOVVNQKCSKSHKT-HNNXBMFYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB03476</td>
      <td>Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine</td>
      <td>NQRIWXVAIWPBEM-OALUTQOASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB07247</td>
      <td>[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA</td>
      <td>SRPOHNDQBDHONJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB12513</td>
      <td>Omaveloxolone</td>
      <td>RJCWBNBKOKFWNY-IDPLTSGASA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB13014</td>
      <td>Hypericin</td>
      <td>BTXNYTINYBABQR-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB02581</td>
      <td>5-[2,3-Dichloro-4-(5-{1-[2-(2-Guanidino-4-Methyl-Pentanoylamino)-Acetyl]-Piperidin-4-Yl}-1-Methyl-1h-Pyrazol-3-Yl)-Phenoxymethyl]-Furan-2-Carboxylic Acid</td>
      <td>VNZHOIDQBPFEJU-OAQYLSRUSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB05611</td>
      <td>Apilimod</td>
      <td>HSKAZIJJKRAJAV-KOEQRZSOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB03466</td>
      <td>BMS184394</td>
      <td>AYAJZQYENGWICE-QHCPKHFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB13454</td>
      <td>Nicomorphine</td>
      <td>HNDXBGYRMHRUFN-CIVUWBIHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB02258</td>
      <td>SR11254</td>
      <td>RNZIUDLOJHVHLZ-VYIQYICTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB03571</td>
      <td>3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-N-(3,5-Dichlorobenzyl)-Benzamide</td>
      <td>JMQTXEWNXSPEKX-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB07270</td>
      <td>N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE</td>
      <td>GAYYMURZGLJDCT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB07530</td>
      <td>(1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol</td>
      <td>PCHUQQNKOFNVDU-OSXMSNBXSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB06638</td>
      <td>Quarfloxin</td>
      <td>WOQIDNWTQOYDLF-CGAIIQECSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB07815</td>
      <td>GIBBERELLIN A4</td>
      <td>RSQSQJNRHICNNH-NFMPGMCNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB07029</td>
      <td>4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE</td>
      <td>QQBNDYARFVOEGW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB03878</td>
      <td>N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide</td>
      <td>YWQVBESSYLICRX-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB03865</td>
      <td>6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine</td>
      <td>FEKRWNWZMOSVBX-UHFFFAOYSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB02112</td>
      <td>Zk-806450</td>
      <td>DZLGSWPXZYDHBD-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB07025</td>
      <td>3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE</td>
      <td>KBIHHEGEALBUMT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB15291</td>
      <td>BMS-986142</td>
      <td>ZRYMMWAJAFUANM-INIZCTEOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB12494</td>
      <td>SGI-1776</td>
      <td>MHXGEROHKGDZGO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB15435</td>
      <td>BMS-986158</td>
      <td>KGERZPVQIRYWRK-GDLZYMKVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB02877</td>
      <td>Arotinoid acid</td>
      <td>FOIVPCKZDPCJJY-JQIJEIRASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB11877</td>
      <td>Basmisanil</td>
      <td>VCGRFBXVSFAGGA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB11979</td>
      <td>Elagolix</td>
      <td>HEAUOKZIVMZVQL-VWLOTQADSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB01329</td>
      <td>Cefoperazone</td>
      <td>GCFBRXLSHGKWDP-XCGNWRKASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB15233</td>
      <td>Avapritinib</td>
      <td>DWYRIWUZIJHQKQ-SANMLTNESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB07831</td>
      <td>2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE</td>
      <td>SHSORWZDEKFFLP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB12121</td>
      <td>Entospletinib</td>
      <td>XSMSNFMDVXXHGJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB15294</td>
      <td>SB-1578</td>
      <td>NNXDIGHYPZHXTR-ONEGZZNKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB12381</td>
      <td>Merestinib</td>
      <td>QHADVLVFMKEIIP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB02629</td>
      <td>Inhibitor Bea403</td>
      <td>LYHLPPXMBKMSSZ-JQFCFGFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB11832</td>
      <td>Crenolanib</td>
      <td>DYNHJHQFHQTFTP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB00673</td>
      <td>Aprepitant</td>
      <td>ATALOFNDEOCMKK-OITMNORJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB14914</td>
      <td>Flortaucipir F-18</td>
      <td>GETAAWDSFUCLBS-SJPDSGJFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB08191</td>
      <td>4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid</td>
      <td>KSFDVNIKNYXUIP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB12742</td>
      <td>Amuvatinib</td>
      <td>FOFDIMHVKGYHRU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB12848</td>
      <td>PF-04217903</td>
      <td>PDMUGYOXRHVNMO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB06977</td>
      <td>(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine</td>
      <td>CAASENZOSQYNPX-HSTJUUNISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB12875</td>
      <td>Mavatrep</td>
      <td>ORDHXXHTBUZRCN-NTEUORMPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB03005</td>
      <td>3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium</td>
      <td>ISUOMOOYAOQQPZ-UHFFFAOYSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB15133</td>
      <td>Tepotinib</td>
      <td>AHYMHWXQRWRBKT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB12381</td>
      <td>Merestinib</td>
      <td>QHADVLVFMKEIIP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB07817</td>
      <td>1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea</td>
      <td>NJPVZSIGDRLLTD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB11725</td>
      <td>Latrepirdine</td>
      <td>JNODQFNWMXFMEV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB02545</td>
      <td>Fexaramine</td>
      <td>VLQTUNDJHLEFEQ-KGENOOAVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB00522</td>
      <td>Bentiromide</td>
      <td>SPPTWHFVYKCNNK-FQEVSTJZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB13109</td>
      <td>PKI-179</td>
      <td>WXUUCRLKXQMWRY-OYRHEFFESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB15327</td>
      <td>Abivertinib</td>
      <td>UOFYSRZSLXWIQB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB06178</td>
      <td>Talotrexin</td>
      <td>NYQPLPNEESYGNO-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB00619</td>
      <td>Imatinib</td>
      <td>KTUFNOKKBVMGRW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB03596</td>
      <td>N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide</td>
      <td>FSRPBGBMEKDSIJ-CYBMUJFWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6CS2</td>
      <td>DB08513</td>
      <td>[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID</td>
      <td>PAIQRYUOBBCBSE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.2</td>
      <td>6LZG</td>
      <td>DB03331</td>
      <td>N-Naphthalen-1-Ylmethyl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</td>
      <td>OARVXDFNTLYMCJ-JVUUKAHWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB06543</td>
      <td>Astaxanthin</td>
      <td>MQZIGYBFDRPAKN-UWFIBFSHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08164</td>
      <td>(3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE</td>
      <td>GOBIXGZJSMAOFV-QRWLVFNGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07458</td>
      <td>3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione</td>
      <td>LBFDERUQORUFIN-KRWDZBQOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB06630</td>
      <td>Anacetrapib</td>
      <td>MZZLGJHLQGUVPN-HAWMADMCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08674</td>
      <td>(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE</td>
      <td>USPFJPDEADLGIG-HSZRJFAPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12415</td>
      <td>Galeterone</td>
      <td>PAFKTGFSEFKSQG-PAASFTFBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB03966</td>
      <td>Clorobiocin</td>
      <td>FJAQNRBDVKIIKK-LFLQOBSNSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB15068</td>
      <td>Agerafenib</td>
      <td>DKNUPRMJNUQNHR-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB05812</td>
      <td>Abiraterone</td>
      <td>GZOSMCIZMLWJML-VJLLXTKPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB13345</td>
      <td>Dihydroergocristine</td>
      <td>DEQITUUQPICUMR-HJPBWRTMSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB13307</td>
      <td>Proscillaridin</td>
      <td>MYEJFUXQJGHEQK-ALRJYLEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB05713</td>
      <td>LY-517717</td>
      <td>VYNKVNDKAOGAAQ-RUZDIDTESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12180</td>
      <td>Apitolisib</td>
      <td>YOVVNQKCSKSHKT-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB15266</td>
      <td>TAK-580</td>
      <td>VWMJHAFYPMOMGF-ZCFIWIBFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB00481</td>
      <td>Raloxifene</td>
      <td>GZUITABIAKMVPG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07937</td>
      <td>2-butoxy-9-(2,6-difluorobenzyl)-N-(2-morpholin-4-ylethyl)-9H-purin-6-amine</td>
      <td>UGZWPZWADDDTRN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB05944</td>
      <td>Varlitinib</td>
      <td>UWXSAYUXVSFDBQ-CYBMUJFWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12414</td>
      <td>Usistapide</td>
      <td>WSYALRNYQFNNGP-WJOKGBTCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB06486</td>
      <td>Enzastaurin</td>
      <td>AXRCEOKUDYDWLF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB08064</td>
      <td>N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA</td>
      <td>NTMADESEDXKNFZ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12309</td>
      <td>GI-181771X</td>
      <td>CABBMMXFOOZVMS-PMERELPUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB02449</td>
      <td>3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid</td>
      <td>ULOTXPTWJAUGGE-MHZLTWQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01289</td>
      <td>Glisoxepide</td>
      <td>ZKUDBRCEOBOWLF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB04761</td>
      <td>PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE]</td>
      <td>NHPBWKYFMTXWAA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB11737</td>
      <td>Icotinib</td>
      <td>QQLKULDARVNMAL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07856</td>
      <td>6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE</td>
      <td>HPWBHQIUIBFTQC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01184</td>
      <td>Domperidone</td>
      <td>FGXWKSZFVQUSTL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB06134</td>
      <td>SNS-314</td>
      <td>FAYAUAZLLLJJGH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB12042</td>
      <td>Ibodutant</td>
      <td>YQYSVMKCMIUCHY-WJOKGBTCSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB15034</td>
      <td>PRI-724</td>
      <td>VHOZWHQPEJGPCC-AZXNYEMZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB04759</td>
      <td>PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(3-METHYL-BENZYLAMIDE)</td>
      <td>GTBUZLPQANSGGE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07179</td>
      <td>3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide</td>
      <td>DXUJQXZHHGJMFM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01831</td>
      <td>Tryptophanyl-5'amp</td>
      <td>IFQVDHDRFCKAAW-SQIXAUHQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08875</td>
      <td>Cabozantinib</td>
      <td>ONIQOQHATWINJY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12020</td>
      <td>Tecovirimat</td>
      <td>CSKDFZIMJXRJGH-VWLPUNTISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB02873</td>
      <td>1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One</td>
      <td>YAWZIQKDHQIHOS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07084</td>
      <td>N-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2-yl)acetamide</td>
      <td>YHKGWOJTUMJPNW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12483</td>
      <td>Copanlisib</td>
      <td>PZBCKZWLPGJMAO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12382</td>
      <td>R-306465</td>
      <td>MUTBJZVSRNUIHA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01836</td>
      <td>[4-(6-Chloro-Naphthalene-2-Sulfonyl)-Piperazin-1-Yl]-(3,4,5,6-Tetrahydro-2h-[1,4']Bipyridinyl-4-Yl)-Methanone</td>
      <td>ZLAKCKVFSRSENR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB11652</td>
      <td>Tucatinib</td>
      <td>SDEAXTCZPQIFQM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12420</td>
      <td>Diazepinomicin</td>
      <td>SALVHVNECODMJP-GNUCVDFRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB11526</td>
      <td>Masitinib</td>
      <td>WJEOLQLKVOPQFV-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08079</td>
      <td>AMG-208</td>
      <td>HEAIZQNMNCHNFD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6lu7</td>
      <td>DB12411</td>
      <td>R-428</td>
      <td>KXMZDGSRSGHMMK-VWLOTQADSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6lu7</td>
      <td>DB14773</td>
      <td>Lifirafenib</td>
      <td>NGFFVZQXSRKHBM-FKBYEOEOSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB04908</td>
      <td>Flibanserin</td>
      <td>PPRRDFIXUUSXRA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB06976</td>
      <td>1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA</td>
      <td>IWOOJEZSDPRYAZ-WFASDCNBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07977</td>
      <td>3-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)THIOPHENE-2-CARBOXYLIC ACID</td>
      <td>CGNHUSCKOHDSMR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07975</td>
      <td>2-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID</td>
      <td>VTGXLCZUWFYELR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB15006</td>
      <td>Flufenoxuron</td>
      <td>RYLHNOVXKPXDIP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB15242</td>
      <td>MK-0533</td>
      <td>STWITCBWQHTJFJ-XMMPIXPASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB15385</td>
      <td>Acebilustat</td>
      <td>GERJIEKMNDGSCS-DQEYMECFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB14844</td>
      <td>ONC-201</td>
      <td>VLULRUCCHYVXOH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08360</td>
      <td>2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE</td>
      <td>BIFHJPUTQBOBGJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB11769</td>
      <td>Funapide</td>
      <td>NEBUOXBYNAHKFV-NRFANRHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12887</td>
      <td>Tazemetostat</td>
      <td>NSQSAUGJQHDYNO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08536</td>
      <td>3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine</td>
      <td>IBUPHWYGVDAASU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB01988</td>
      <td>6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine</td>
      <td>WFSFNKVFXLIZIY-MHZLTWQESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01126</td>
      <td>Dutasteride</td>
      <td>JWJOTENAMICLJG-QWBYCMEYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB15006</td>
      <td>Flufenoxuron</td>
      <td>RYLHNOVXKPXDIP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12280</td>
      <td>AZD-5423</td>
      <td>FCNQMDSJHADDFT-WNSKOXEYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB00845</td>
      <td>Clofazimine</td>
      <td>WDQPAMHFFCXSNU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB00966</td>
      <td>Telmisartan</td>
      <td>RMMXLENWKUUMAY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB06922</td>
      <td>2-[(1R)-1-carboxy-2-naphthalen-1-ylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid</td>
      <td>CZNPWASYMRBJCX-GOSISDBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB15305</td>
      <td>Risdiplam</td>
      <td>ASKZRYGFUPSJPN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01259</td>
      <td>Lapatinib</td>
      <td>BCFGMOOMADDAQU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07978</td>
      <td>2-({[2,3,5,6-TETRAFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENTA-1,3-DIENE-1-CARBOXYLIC ACID</td>
      <td>ULMUPVXFUDHRGH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB15232</td>
      <td>Telaglenastat</td>
      <td>PRAAPINBUWJLGA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07691</td>
      <td>2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid</td>
      <td>GYILVHHTCYNIOS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB03453</td>
      <td>(R)ÔÇöN[2-[1-(aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-(phenylethynyl)-l-phenylalanine methylester</td>
      <td>MRNGXYMKYHNMLV-PKTZIBPZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB00444</td>
      <td>Teniposide</td>
      <td>NRUKOCRGYNPUPR-QBPJDGROSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08460</td>
      <td>3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile</td>
      <td>KXDIHAQCVNNLIB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12272</td>
      <td>Vidupiprant</td>
      <td>PFWVGKROPKKEDW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB09143</td>
      <td>Sonidegib</td>
      <td>VZZJRYRQSPEMTK-CALCHBBNSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB06945</td>
      <td>N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide</td>
      <td>FOSWRYKPHVPIDJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07680</td>
      <td>[(1S)-1-(5-CHLORO-1-BENZOTHIEN-3-YL)-2-(2-NAPHTHYLAMINO)-2-OXOETHYL]PHOSPHONIC ACID</td>
      <td>HUJXISJLAPAFBO-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12703</td>
      <td>Omipalisib</td>
      <td>CGBJSGAELGCMKE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB14982</td>
      <td>Miransertib</td>
      <td>HNFMVVHMKGFCMB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB14982</td>
      <td>Miransertib</td>
      <td>HNFMVVHMKGFCMB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB08386</td>
      <td>2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline</td>
      <td>VRWJZGHUCOFGPZ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07066</td>
      <td>2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE</td>
      <td>LJAHIGGEXIWVJG-LLVKDONJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB02354</td>
      <td>4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine</td>
      <td>IRKPNOLLMNHSOU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6lu7</td>
      <td>DB05984</td>
      <td>RAF-265</td>
      <td>YABJJWZLRMPFSI-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB04696</td>
      <td>4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN</td>
      <td>GFGZCXHXQCQRFP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08353</td>
      <td>2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE</td>
      <td>NCVMTHVSAJMOPI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB08036</td>
      <td>6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one</td>
      <td>MEXUTNIFSHFQRG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB03311</td>
      <td>3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide</td>
      <td>SXKBTDJJEQQEGE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01267</td>
      <td>Paliperidone</td>
      <td>PMXMIIMHBWHSKN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB11262</td>
      <td>Bisoctrizole</td>
      <td>FQUNFJULCYSSOP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08043</td>
      <td>1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA</td>
      <td>DDDLGNOZDKDSEG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB14675</td>
      <td>Temsavir</td>
      <td>QRPZBKAMSFHVRW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB08351</td>
      <td>N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide</td>
      <td>MNEXDVSJIUQQRH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB15183</td>
      <td>Fosmanogepix</td>
      <td>JQONJQKKVAHONF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB13766</td>
      <td>Lidoflazine</td>
      <td>ZBIAKUMOEKILTF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB03141</td>
      <td>3-{[(5R,6R)-5-Benzyl-6-hydroxy-2,4-bis(4-hydroxybenzyl)-3-oxo-1,2,4-triazepan-1-yl]sulfonyl}benzonitril</td>
      <td>UYUWNNRWESUYOB-FIRIVFDPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08305</td>
      <td>(3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide</td>
      <td>KQAGZLQCEURCKJ-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12558</td>
      <td>AEE-788</td>
      <td>OONFNUWBHFSNBT-HXUWFJFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB12550</td>
      <td>Taladegib</td>
      <td>SZBGQDXLNMELTB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB06448</td>
      <td>Lonafarnib</td>
      <td>DHMTURDWPRKSOA-RUZDIDTESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB14581</td>
      <td>CPI-1205</td>
      <td>HPODOLXTMDHLLC-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07026</td>
      <td>(1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE</td>
      <td>PPLDARNGJSQINK-OKZBNKHCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB12590</td>
      <td>Indiplon</td>
      <td>CBIAWPMZSFFRGN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07267</td>
      <td>2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine</td>
      <td>JONFDFIXMPXTRH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB03159</td>
      <td>CRA_8696</td>
      <td>GAVRMVQHHVMXFD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB12644</td>
      <td>AZD-2066</td>
      <td>SXWHYTICXCLKDG-GFCCVEGCSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB04698</td>
      <td>N-(1,4-DIHYDRO-5H-TETRAZOL-5-YLIDENE)-9-OXO-9H-XANTHENE-2-SULFONAMIDE</td>
      <td>HJWYZPGYPZNDTN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB15403</td>
      <td>Ziritaxestat</td>
      <td>REQQVBGILUTQNN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB05105</td>
      <td>Pleconaril</td>
      <td>KQOXLKOJHVFTRN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB05171</td>
      <td>E-2012</td>
      <td>PUOAETJYKQITMO-LANLRWRYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB14768</td>
      <td>PF-06459988</td>
      <td>ODMXWZROLKITMS-RISCZKNCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB01349</td>
      <td>Tasosartan</td>
      <td>ADXGNEYLLLSOAR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6LZG</td>
      <td>DB15023</td>
      <td>BMS-791826</td>
      <td>DZBKAUMYTFPJIS-QHCPKHFHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB08995</td>
      <td>Diosmin</td>
      <td>GZSOSUNBTXMUFQ-YFAPSIMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB06999</td>
      <td>N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide</td>
      <td>YZDJQTHVDDOVHR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB13610</td>
      <td>Flumedroxone</td>
      <td>CDZJOBWKHSYNMO-SCUQKFFVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.1</td>
      <td>6CS2</td>
      <td>DB07570</td>
      <td>3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID</td>
      <td>ZKEZEXYKYHYIMQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB03591</td>
      <td>RU82209</td>
      <td>LVZDQVATAQEMCX-NSOVKSMOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB01419</td>
      <td>Antrafenine</td>
      <td>NWGGKKGAFZIVBJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08749</td>
      <td>3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE</td>
      <td>KTRFBFMYAJOXLG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07941</td>
      <td>PH-797804</td>
      <td>KCAJXIDMCNPGHZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB00549</td>
      <td>Zafirlukast</td>
      <td>YEEZWCHGZNKEEK-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07783</td>
      <td>1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE</td>
      <td>GUYYFMCFEPDDFL-OAQYLSRUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB06429</td>
      <td>Talnetant</td>
      <td>BIAVGWDGIJKWRM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB15269</td>
      <td>ALK-4290</td>
      <td>DWKNOLCXIFYNFV-HSZRJFAPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB02732</td>
      <td>Nicotinamide Adenine Dinucleotide Acetone Adduct</td>
      <td>SGHBFOOIAAJJMI-YDKVLQLQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB13472</td>
      <td>Cyclofenil</td>
      <td>GVOUFPWUYJWQSK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07237</td>
      <td>{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone</td>
      <td>VUWFJUJWAWMRQN-HXUWFJFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB14942</td>
      <td>BMS-986141</td>
      <td>KEEBLYWBELVGPQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12345</td>
      <td>MBX-2982</td>
      <td>NFTMKHWBOINJGM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB01873</td>
      <td>Epothilone D</td>
      <td>XOZIUKBZLSUILX-GIQCAXHBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB00773</td>
      <td>Etoposide</td>
      <td>VJJPUSNTGOMMGY-MRVIYFEKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB06755</td>
      <td>Beta carotene</td>
      <td>OENHQHLEOONYIE-JLTXGRSLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB15186</td>
      <td>GDC-0084</td>
      <td>LGWACEZVCMBSKW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12941</td>
      <td>ODM-201</td>
      <td>BLIJXOOIHRSQRB-PXYINDEMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB15189</td>
      <td>Birabresib</td>
      <td>GNMUEVRJHCWKTO-FQEVSTJZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB04739</td>
      <td>4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE</td>
      <td>JHMBUEWQJDGKGS-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12903</td>
      <td>DEBIO-1347</td>
      <td>BEMNJULZEQTDJY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12892</td>
      <td>MGB-BP-3</td>
      <td>OEKXCVYZBVOWBR-BQYQJAHWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08538</td>
      <td>N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>HQPVGVSQPQVZLD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB01342</td>
      <td>Forasartan</td>
      <td>YONOBYIBNBCDSJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB03791</td>
      <td>(3-{3-[[2-Chloro-3-(Trifluoromethyl)Benzyl](2,2-Diphenylethyl)Amino]Propoxy}Phenyl)Acetic Acid</td>
      <td>NAXSRXHZFIBFMI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08406</td>
      <td>[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE</td>
      <td>NXCCIJQEAKMFGW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12746</td>
      <td>AKN-028</td>
      <td>JLRIJKVMMZEKDF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB07817</td>
      <td>1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea</td>
      <td>NJPVZSIGDRLLTD-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12579</td>
      <td>JNJ-37822681</td>
      <td>UVUYWJWYRLJHEN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12985</td>
      <td>Quisinostat</td>
      <td>PAWIYAYFNXQGAP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12550</td>
      <td>Taladegib</td>
      <td>SZBGQDXLNMELTB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB11662</td>
      <td>Rabusertib</td>
      <td>SYYBDNPGDKKJDU-ZDUSSCGKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB12382</td>
      <td>R-306465</td>
      <td>MUTBJZVSRNUIHA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07879</td>
      <td>N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide</td>
      <td>SMSIXMLQOONOQQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07168</td>
      <td>[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile</td>
      <td>MFMSRHREFZCFSN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB13101</td>
      <td>4SC-202</td>
      <td>PRXXYMVLYKJITB-IZZDOVSWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12419</td>
      <td>HSD-016</td>
      <td>ZWASRJHIEFYJGL-BFUOFWGJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB13080</td>
      <td>Roluperidone</td>
      <td>RNRYULFRLCBRQS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08703</td>
      <td>12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one</td>
      <td>FGKKIHITEICGMN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB13052</td>
      <td>Upamostat</td>
      <td>HUASEDVYRABWCV-NDEPHWFRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB04669</td>
      <td>TRIAZOLOPYRIMIDINE</td>
      <td>YWBFPKPWMSWWEA-UHFFFAOYSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12504</td>
      <td>JNJ-40346527</td>
      <td>BNVPFDRNGHMRJS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08241</td>
      <td>4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE</td>
      <td>RUUOIINPNMNPIU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB15247</td>
      <td>Vorolanib</td>
      <td>KMIOJWCYOHBUJS-HAKPAVFJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB03957</td>
      <td>SP2456</td>
      <td>SSSXBBASYYVGCI-HSZRJFAPSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07054</td>
      <td>(2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL</td>
      <td>OSCWQKTUILTARV-MRXNPFEDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08143</td>
      <td>5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE</td>
      <td>SXIYSYYSKHUTQQ-RDJZCZTQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB01908</td>
      <td>RU85493</td>
      <td>MWEWSHNGVWABKG-SVBPBHIXSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07359</td>
      <td>3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide</td>
      <td>SJTQKYKXCYVFHX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB14822</td>
      <td>SB-649868</td>
      <td>ZJXIUGNEAIHSBI-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB08022</td>
      <td>(2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile</td>
      <td>RCYPVQCPYKNSTG-OAHLLOKOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB11740</td>
      <td>MK-1775</td>
      <td>BKWJAKQVGHWELA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08865</td>
      <td>Crizotinib</td>
      <td>KTEIFNKAUNYNJU-GFCCVEGCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB01219</td>
      <td>Dantrolene</td>
      <td>OZOMQRBLCMDCEG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12134</td>
      <td>Gepotidacin</td>
      <td>PZFAZQUREQIODZ-LJQANCHMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB14856</td>
      <td>PF-05089771</td>
      <td>ZYSCOUXLBXGGIM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB02194</td>
      <td>8-Benzyl-2-Hydroxy-2-(4-Hydroxy-Benzyl)-6-(4-Hydroxy-Phenyl)-2h-Imidazo[1,2-a]Pyrazin-3-One</td>
      <td>ULLMMKZQNNBLRN-SANMLTNESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB14703</td>
      <td>Dexamethasone metasulfobenzoate</td>
      <td>TWQWRHIQRAZHPR-XNXCGYEVSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB11925</td>
      <td>Vistusertib</td>
      <td>JUSFANSTBFGBAF-IRXDYDNUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB04172</td>
      <td>[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine</td>
      <td>WATXEHGLYJKXOF-NDEPHWFRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB15071</td>
      <td>Omidenepag isopropyl</td>
      <td>VIQCWEGEHRBLAC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB04107</td>
      <td>[(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester</td>
      <td>RNOYCNIZOAIUSV-LSWMGQQCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07430</td>
      <td>(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one</td>
      <td>CMWRPDHVGMHLSZ-GFCCVEGCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB06169</td>
      <td>Indibulin</td>
      <td>SOLIIYNRSAWTSQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB04330</td>
      <td>Bilh 434</td>
      <td>KNRVCCXHLSHTFW-HGPRPZRGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB13764</td>
      <td>Monoxerutin</td>
      <td>MBHXKZDTQCSVPM-BDAFLREQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB04852</td>
      <td>Implitapide</td>
      <td>AMNXBQPRODZJQR-DITALETJSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB03336</td>
      <td>BIA</td>
      <td>KVIVJQWOYSWCCZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07397</td>
      <td>(5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide</td>
      <td>ITADELAVAWJACR-NSHDSACASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB11896</td>
      <td>Gedatolisib</td>
      <td>DWZAEMINVBZMHQ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB08006</td>
      <td>N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine</td>
      <td>OXYDLVAOXASTMW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB09048</td>
      <td>Netupitant</td>
      <td>WAXQNWCZJDTGBU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB13931</td>
      <td>Netarsudil</td>
      <td>OURRXQUGYQRVML-AREMUKBSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB06190</td>
      <td>Solabegron</td>
      <td>LLDXOPKUNJTIRF-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07608</td>
      <td>N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide</td>
      <td>JDGOPNUGILVNJZ-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB11765</td>
      <td>PF-04991532</td>
      <td>GKMLFBRLRVQVJO-ZDUSSCGKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB15011</td>
      <td>Avacopan</td>
      <td>PUKBOVABABRILL-YZNIXAGQSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07605</td>
      <td>2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE</td>
      <td>DHDQMXPAANQKDC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08861</td>
      <td>DPDPE</td>
      <td>MCMMCRYPQBNCPH-WMIMKTLMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12054</td>
      <td>BQ-123</td>
      <td>VYCMAAOURFJIHD-PJNXIOHISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB15450</td>
      <td>PF-05105679</td>
      <td>BXNMZRPTQFVRFA-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB11867</td>
      <td>JNJ-39393406</td>
      <td>IURMHZBQEYNQOH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB15416</td>
      <td>PX-102</td>
      <td>XBUXXJUEBFDQHD-NHCUHLMSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB12012</td>
      <td>PF-04457845</td>
      <td>BATCTBJIJJEPHM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB15408</td>
      <td>Silmitasertib</td>
      <td>MUOKSQABCJCOPU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB15343</td>
      <td>HM-43239</td>
      <td>FZLSDZZNPXXBBB-KDURUIRLSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB06350</td>
      <td>Elinogrel</td>
      <td>LGSDFTPAICUONK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB11786</td>
      <td>Pefcalcitol</td>
      <td>SVCSMAZYWOQCBW-NVJMFHFGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07528</td>
      <td>3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one</td>
      <td>HXUZQEYFKAZBPX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07537</td>
      <td>N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide</td>
      <td>CLEGTVIMOPPIBR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB15028</td>
      <td>MK-1064</td>
      <td>CKTWQGHVNRYNCM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07756</td>
      <td>1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL</td>
      <td>GPBGHVRNVGXPNM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB01251</td>
      <td>Gliquidone</td>
      <td>LLJFMFZYVVLQKT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB03104</td>
      <td>RU82129</td>
      <td>NKMPOVPTYDXGEC-MNRBYUMSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB01167</td>
      <td>Itraconazole</td>
      <td>VHVPQPYKVGDNFY-ZPGVKDDISA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12198</td>
      <td>Fosdagrocorat</td>
      <td>BVXLAHSJXXSWFF-KEKPKEOLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07765</td>
      <td>METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE</td>
      <td>UKCFUFHREWUXJJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB03523</td>
      <td>Brequinar</td>
      <td>PHEZJEYUWHETKO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07255</td>
      <td>N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE</td>
      <td>PNEWIQAEGKQNCE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB01745</td>
      <td>N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)Isopipecolinic Acid Methyl Ester</td>
      <td>JJLGQWCKMHPBEB-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB04285</td>
      <td>{4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid</td>
      <td>GBLDYRVJENYQNH-AGLOJYHOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB09076</td>
      <td>Umeclidinium</td>
      <td>FVTWTVQXNAJTQP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB11830</td>
      <td>Mocetinostat</td>
      <td>HRNLUBSXIHFDHP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB01761</td>
      <td>4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine</td>
      <td>QICPQLFMWYQJGX-SFHVURJKSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07456</td>
      <td>3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione</td>
      <td>LBFDERUQORUFIN-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB07700</td>
      <td>3-CARBOXAMIDO-1,3,5(10)-ESTRATRIEN-17(R)-SPIRO-2'(5',5'-DIMETHYL-6'OXO)TETRAHYDROPYRAN</td>
      <td>YVAJWBACBRSVPR-NDUHRLLKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB08912</td>
      <td>Dabrafenib</td>
      <td>BFSMGDJOXZAERB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6LZG</td>
      <td>DB05454</td>
      <td>Paliroden</td>
      <td>CNEWKIDCGDXBDE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB12001</td>
      <td>Abemaciclib</td>
      <td>UZWDCWONPYILKI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB13687</td>
      <td>Niaprazine</td>
      <td>RSKQGBFMNPDPLR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB03038</td>
      <td>LY341770</td>
      <td>MXAFDBCLWLMXSI-ZDUSSCGKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB00354</td>
      <td>Buclizine</td>
      <td>MOYGZHXDRJNJEP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-9.0</td>
      <td>6CS2</td>
      <td>DB05608</td>
      <td>MKC-1</td>
      <td>OVSKGTONMLKNPZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08015</td>
      <td>(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime</td>
      <td>SZYREAUDQRVVLV-DAFNUICNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11894</td>
      <td>Efatutazone</td>
      <td>JCYNMRJCUYVDBC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB05616</td>
      <td>4'-Methylene-5,8,10-trideazaaminopterin</td>
      <td>NAWXUBYGYWOOIX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB00878</td>
      <td>Chlorhexidine</td>
      <td>GHXZTYHSJHQHIJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB00799</td>
      <td>Tazarotene</td>
      <td>OGQICQVSFDPSEI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB07545</td>
      <td>N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE</td>
      <td>RDTDWGQDFJPTPD-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB03895</td>
      <td>Malachite Green</td>
      <td>VFCNQNZNPKRXIT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08031</td>
      <td>N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE</td>
      <td>LNQWELVSNCYKDU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11921</td>
      <td>Deflazacort</td>
      <td>FBHSPRKOSMHSIF-GRMWVWQJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11949</td>
      <td>Vestipitant</td>
      <td>SBBYBXSFWOLDDG-JLTOFOAXSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11764</td>
      <td>Spebrutinib</td>
      <td>KXBDTLQSDKGAEB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08916</td>
      <td>Afatinib</td>
      <td>ULXXDDBFHOBEHA-CWDCEQMOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08572</td>
      <td>4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE</td>
      <td>YBKLJTXDSBEVRV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB14675</td>
      <td>Temsavir</td>
      <td>QRPZBKAMSFHVRW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB15247</td>
      <td>Vorolanib</td>
      <td>KMIOJWCYOHBUJS-HAKPAVFJSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07546</td>
      <td>[1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid</td>
      <td>BBYRUZKRFAIQSR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB14942</td>
      <td>BMS-986141</td>
      <td>KEEBLYWBELVGPQ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12635</td>
      <td>Aleplasinin</td>
      <td>HSXLMAFNWCSZGP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB03207</td>
      <td>2-(Biphenyl-4-Sulfonyl)-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid</td>
      <td>BNVMUDXGABBWGP-OAQYLSRUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15356</td>
      <td>SLV-334</td>
      <td>LOFDNSDPZTVIIO-VPUSJEBWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12696</td>
      <td>BMS-582949</td>
      <td>GDTQLZHHDRRBEB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07987</td>
      <td>[2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER</td>
      <td>AWAKNMKLVLWIIQ-OAHLLOKOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB00278</td>
      <td>Argatroban</td>
      <td>KXNPVXPOPUZYGB-IOVMHBDKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB08387</td>
      <td>2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline</td>
      <td>AZEXWHKOMMASPA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08490</td>
      <td>CTS-1027</td>
      <td>ROSNVSQTEGHUKU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12796</td>
      <td>MRX-I</td>
      <td>SULYVXZZUMRQAX-NSHDSACASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB01940</td>
      <td>Balanol Analog 2</td>
      <td>SQLYTJZXRRDERK-ISKFKSNPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB06940</td>
      <td>N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide</td>
      <td>ZZTMFGIGOADCFX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB11786</td>
      <td>Pefcalcitol</td>
      <td>SVCSMAZYWOQCBW-NVJMFHFGSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11800</td>
      <td>Tivozanib</td>
      <td>SPMVMDHWKHCIDT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB12784</td>
      <td>NS-018</td>
      <td>UQTPDWDAYHAZNT-AWEZNQCLSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15328</td>
      <td>Ubrogepant</td>
      <td>DDOOFTLHJSMHLN-ZQHRPCGSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB04875</td>
      <td>Pralnacasan</td>
      <td>CXAGHAZMQSCAKJ-WAHHBDPQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB07837</td>
      <td>[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid</td>
      <td>SWXKLXXVFMYMDP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB04583</td>
      <td>5-Carbamoyl-1,1':4',1''-terphenyl-3-carboxylic acid</td>
      <td>LAZPCGBRHLARSI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>1R42</td>
      <td>DB02741</td>
      <td>CD564</td>
      <td>RWYREGSYPCNZTL-UHFFFAOYSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB00872</td>
      <td>Conivaptan</td>
      <td>IKENVDNFQMCRTR-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11829</td>
      <td>Ruboxistaurin</td>
      <td>ZCBUQCWBWNUWSU-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB05129</td>
      <td>Elsamitrucin</td>
      <td>MGQRRMONVLMKJL-KWJIQSIXSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6lu7</td>
      <td>DB08450</td>
      <td>N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine</td>
      <td>HNHRWNUXTCATSG-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6lu7</td>
      <td>DB11791</td>
      <td>Capmatinib</td>
      <td>LIOLIMKSCNQPLV-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB11891</td>
      <td>CUDC-907</td>
      <td>JOWXJLIFIIOYMS-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12640</td>
      <td>CP-609754</td>
      <td>JAHDAIPFBPPQHQ-GDLZYMKVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB06997</td>
      <td>2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide</td>
      <td>BMPOCDJEXAXXEZ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB03460</td>
      <td>Violaxanthin</td>
      <td>SZCBXWMUOPQSOX-WVJDLNGLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB15396</td>
      <td>PF-114</td>
      <td>SLIVDYMORZGPLW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11871</td>
      <td>PF-00610355</td>
      <td>YPHDIMUXXABSSO-YTTGMZPUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB14821</td>
      <td>Macozinone</td>
      <td>BJDZBXGJNBMCAV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15393</td>
      <td>Telatinib</td>
      <td>QFCXANHHBCGMAS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11853</td>
      <td>Relugolix</td>
      <td>AOMXMOCNKJTRQP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB01908</td>
      <td>RU85493</td>
      <td>MWEWSHNGVWABKG-SVBPBHIXSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB06995</td>
      <td>N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide</td>
      <td>USBSTVPJNQLYEM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB04477</td>
      <td>N-1,2,3,4-Tetrahydronaphth-1-Yl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</td>
      <td>FDZQGEIYGFPMOB-ZUURFMEUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12874</td>
      <td>Quizartinib</td>
      <td>CVWXJKQAOSCOAB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB06985</td>
      <td>2-[({4-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)amino]benzoic acid</td>
      <td>MEAQCLPMSVEOQF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB12669</td>
      <td>4SC-203</td>
      <td>MAFACRSJGNJHCF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB01977</td>
      <td>6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine</td>
      <td>AECPTICWHONWNW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6lu7</td>
      <td>DB12323</td>
      <td>Radotinib</td>
      <td>DUPWHXBITIZIKZ-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB12857</td>
      <td>NVP-LEQ-506</td>
      <td>POERAARDVFVDLO-QGZVFWFLSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB14995</td>
      <td>NP-G2-044</td>
      <td>XLLRLAABUFOJPC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07827</td>
      <td>4-{[1-METHYL-2,4-DIOXO-6-(3-PHENYLPROP-1-YN-1-YL)-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHYL}BENZOIC ACID</td>
      <td>FLTYDFYSVZBKOB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB02128</td>
      <td>[1-(3-Hydroxy-2-Oxo-1-Phenethyl-Propylcarbamoyl)2-Phenyl-Ethyl]-Carbamic Acid Pyridin-4-Ylmethyl Ester</td>
      <td>QCUBCTPTNWPFBC-ZEQRLZLVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07769</td>
      <td>S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE</td>
      <td>KJMFOTCDISOHDX-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12523</td>
      <td>Mizolastine</td>
      <td>PVLJETXTTWAYEW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11637</td>
      <td>Delamanid</td>
      <td>XDAOLTSRNUSPPH-XMMPIXPASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15170</td>
      <td>Evobrutinib</td>
      <td>QUIWHXQETADMGN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15047</td>
      <td>BMS-919373</td>
      <td>XGKULQQVQWCASY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15273</td>
      <td>VS-4718</td>
      <td>IGUBBWJDMLCRIK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB06212</td>
      <td>Tolvaptan</td>
      <td>GYHCTFXIZSNGJT-XMMPIXPASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB00878</td>
      <td>Chlorhexidine</td>
      <td>GHXZTYHSJHQHIJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB06590</td>
      <td>Ceftaroline fosamil</td>
      <td>ZCCUWMICIWSJIX-NQJJCJBVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB07362</td>
      <td>1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea</td>
      <td>UOLCZAFAGDOUFX-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB07152</td>
      <td>N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide</td>
      <td>TYPILNNEZPSNTI-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08207</td>
      <td>2-(3,5-DIMETHYLPHENYL)-1,3-BENZOXAZOLE</td>
      <td>BIHLSRJPJFOESJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB04020</td>
      <td>4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol</td>
      <td>AIBKIFHSQQYXLG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB01395</td>
      <td>Drospirenone</td>
      <td>METQSPRSQINEEU-HXCATZOESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB04016</td>
      <td>2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid</td>
      <td>XUJQPDQURBZEGJ-KXQOOQHDSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB13094</td>
      <td>Pruvanserin</td>
      <td>AQRLDDAFYYAIJP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB15036</td>
      <td>Sitravatinib</td>
      <td>WLAVZAAODLTUSW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15056</td>
      <td>Bifenthrin</td>
      <td>OMFRMAHOUUJSGP-IRHGGOMRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15065</td>
      <td>PF-06291874</td>
      <td>IBDYYOQKQCCSDP-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB07189</td>
      <td>(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid</td>
      <td>BFZXMIUWGSTUAL-ZSOKXDGFSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15121</td>
      <td>AT-001</td>
      <td>YRGPAXAVTDMKDK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB04841</td>
      <td>Flunarizine</td>
      <td>SMANXXCATUTDDT-QPJJXVBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB07261</td>
      <td>THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDE</td>
      <td>NVKDOURNRJCKJE-INIZCTEOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12225</td>
      <td>Beclabuvir</td>
      <td>ZTTKEBYSXUCBSE-QDFUAKMASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB03067</td>
      <td>4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid</td>
      <td>VFYAZSTYKPFSFL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12214</td>
      <td>Luseogliflozin</td>
      <td>WHSOLWOTCHFFBK-ZQGJOIPISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08815</td>
      <td>Lurasidone</td>
      <td>PQXKDMSYBGKCJA-CVTJIBDQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB06321</td>
      <td>R-348</td>
      <td>IGLNXKVGKIFNBQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07142</td>
      <td>5-[(3R)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine</td>
      <td>ATFDKOLABYIYCC-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12307</td>
      <td>Foretinib</td>
      <td>CXQHYVUVSFXTMY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB02106</td>
      <td>[3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid</td>
      <td>KIRQJXNQGZAKGR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB11737</td>
      <td>Icotinib</td>
      <td>QQLKULDARVNMAL-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11691</td>
      <td>Naldemedine</td>
      <td>AXQACEQYCPKDMV-RZAWKFBISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB08143</td>
      <td>5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE</td>
      <td>SXIYSYYSKHUTQQ-RDJZCZTQSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12332</td>
      <td>Rucaparib</td>
      <td>HMABYWSNWIZPAG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07297</td>
      <td>5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE</td>
      <td>PTILEOLOGGMFCS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12355</td>
      <td>Netazepide</td>
      <td>YDZYKNJZCVIKPP-VWLOTQADSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB13407</td>
      <td>Nifenazone</td>
      <td>BRZANEXCSZCZCI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB13950</td>
      <td>WIN 55212-2</td>
      <td>HQVHOQAKMCMIIM-HXUWFJFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB13552</td>
      <td>Trifluperidol</td>
      <td>GPMXUUPHFNMNDH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07453</td>
      <td>2-PHENYL-4H-BENZO[H]CHROMEN-4-ONE</td>
      <td>VFMMPHCGEFXGIP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07460</td>
      <td>2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE</td>
      <td>UYJNQQDJUOUFQJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB15168</td>
      <td>Cilofexor</td>
      <td>KZSKGLFYQAYZCO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11176</td>
      <td>Zeaxanthin</td>
      <td>JKQXZKUSFCKOGQ-QAYBQHTQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB08237</td>
      <td>2'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate)</td>
      <td>COMPKRGNHXOXMN-GVDBMIGSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB02705</td>
      <td>6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</td>
      <td>DARQQJKHXPXSRO-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB12522</td>
      <td>Toreforant</td>
      <td>FCRFVPZAXGJLPW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07426</td>
      <td>[1-HYDROXY-2-(1,1':3',1''-TERPHENYL-3-YLOXY)ETHANE-1,1-DIYL]BIS(PHOSPHONIC ACID)</td>
      <td>NWIARQRYIRVYCM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB06666</td>
      <td>Lixivaptan</td>
      <td>PPHTXRNHTVLQED-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11978</td>
      <td>Glasdegib</td>
      <td>SFNSLLSYNZWZQG-VQIMIIECSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB11995</td>
      <td>Avatrombopag</td>
      <td>OFZJKCQENFPZBH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6LZG</td>
      <td>DB06011</td>
      <td>AMG-222</td>
      <td>NVSWJKWHLUTHLP-CPJSRVTESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07507</td>
      <td>2-(4-hydroxybiphenyl-3-yl)-4-methyl-1H-isoindole-1,3(2H)-dione</td>
      <td>ROMNEYAQUBNRLR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB07140</td>
      <td>5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine</td>
      <td>JPENSYBRTSIYGO-AWEZNQCLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB13991</td>
      <td>Pipequaline</td>
      <td>AMEWZCMTSIONOX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB11616</td>
      <td>Pirarubicin</td>
      <td>KMSKQZKKOZQFFG-YXRRJAAWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB04238</td>
      <td>N-Alpha-(2-Naphthylsulfonyl)-N-(3-Amidino-L-Phenylalaninyl)-D-Pipecolinic Acid</td>
      <td>GNANSBQAIRJZPA-XZOQPEGZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.9</td>
      <td>6CS2</td>
      <td>DB14128</td>
      <td>Nadide</td>
      <td>BAWFJGJZGIEFAR-NNYOXOHSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11273</td>
      <td>Dihydroergocornine</td>
      <td>SEALOBQTUQIVGU-QNIJNHAOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB12561</td>
      <td>WNT-974</td>
      <td>XXYGTCZJJLTAGH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB02466</td>
      <td>4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid</td>
      <td>ZXQHMEUGMCXKLO-KPKJPENVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB12318</td>
      <td>BMS-599626</td>
      <td>LUJZZYWHBDHDQX-QFIPXVFZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07666</td>
      <td>(3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE</td>
      <td>OAWGQHXWGXOUKV-BEFAXECRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11759</td>
      <td>Pevonedistat</td>
      <td>MPUQHZXIXSTTDU-QXGSTGNESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB08896</td>
      <td>Regorafenib</td>
      <td>FNHKPVJBJVTLMP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12512</td>
      <td>Verucerfont</td>
      <td>VKHVAUKFLBBZFJ-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03181</td>
      <td>2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione</td>
      <td>RXQAVKWRCZYGMV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12185</td>
      <td>Exatecan</td>
      <td>ZVYVPGLRVWUPMP-FYSMJZIKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08739</td>
      <td>2-{3-[(2S)-4,4-difluoro-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]-3-oxopropyl}-isoindole-1,3(2H)-dione</td>
      <td>ZSXNPAWXICXNGZ-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11775</td>
      <td>PF-03758309</td>
      <td>AYCPARAPKDAOEN-LJQANCHMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07405</td>
      <td>1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE</td>
      <td>GIZYIOOBBUHOBS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08816</td>
      <td>Ticagrelor</td>
      <td>OEKWJQXRCDYSHL-FNOIDJSQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11712</td>
      <td>Tezacaftor</td>
      <td>MJUVRTYWUMPBTR-MRXNPFEDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08248</td>
      <td>3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE</td>
      <td>BKDUVKJYBJDZQW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB11791</td>
      <td>Capmatinib</td>
      <td>LIOLIMKSCNQPLV-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08095</td>
      <td>3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA</td>
      <td>ZWYFTKPEHRQCCW-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07697</td>
      <td>1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine</td>
      <td>HMGDKYUJSFVHIY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07254</td>
      <td>N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE</td>
      <td>KQGTYXRWSIBDOZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12285</td>
      <td>Verubecestat</td>
      <td>YHYKUSGACIYRML-KRWDZBQOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07215</td>
      <td>2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID</td>
      <td>ILUPZUOBHCUBKB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB07256</td>
      <td>3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE</td>
      <td>ZVQZIVCQLFGXFZ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB07691</td>
      <td>2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid</td>
      <td>GYILVHHTCYNIOS-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB11734</td>
      <td>Fedovapagon</td>
      <td>RUOLFWZIFNQQGH-DEOSSOPVSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07265</td>
      <td>3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID</td>
      <td>JDARUOOLJCFUOY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB02155</td>
      <td>Balanol Analog 8</td>
      <td>XVLMXAUKCDSMMW-YXLARRHKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11274</td>
      <td>Dihydro-alpha-ergocryptine</td>
      <td>PBUNVLRHZGSROC-VTIMJTGVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03072</td>
      <td>2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone</td>
      <td>LOFDUAJQRUYHBR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11971</td>
      <td>Vilaprisan</td>
      <td>JUFWQQVHQFDUOD-ANRPBIDPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08597</td>
      <td>6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine</td>
      <td>XHBVYDAKJHETMP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB08674</td>
      <td>(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE</td>
      <td>USPFJPDEADLGIG-HSZRJFAPSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03173</td>
      <td>CRA_10433</td>
      <td>CFSQPEBVGUSQII-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07289</td>
      <td>5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID</td>
      <td>XEQPGVUGYAUMSA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07607</td>
      <td>4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE</td>
      <td>RXDZANYWRNIAOR-HHHXNRCGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07360</td>
      <td>1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea</td>
      <td>JJHXPDTVQKWKHA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB00826</td>
      <td>Natamycin</td>
      <td>NCXMLFZGDNKEPB-FFPOYIOWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08339</td>
      <td>6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE</td>
      <td>ZIQFYVPVJZEOFS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12082</td>
      <td>Vesnarinone</td>
      <td>ZVNYJIZDIRKMBF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB02009</td>
      <td>L-756,423</td>
      <td>AOMZDQMIOCTPQP-QHQMVRJISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11742</td>
      <td>Ebastine</td>
      <td>MJJALKDDGIKVBE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07396</td>
      <td>1-{2-[3-(2-Chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid</td>
      <td>KAJJGOCSAXKXBD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB12457</td>
      <td>Rimegepant</td>
      <td>KRNAOFGYEFKHPB-ANJVHQHFSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07126</td>
      <td>O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE</td>
      <td>OWXORKPNCHJYOF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08950</td>
      <td>Indoramin</td>
      <td>JXZZEXZZKAWDSP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07145</td>
      <td>(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE</td>
      <td>YDMIPBHQKFOFQW-NSYGIPOTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB07586</td>
      <td>5-(4-METHYL-BENZOYLAMINO)-BIPHENYL-3,4'-DICARBOXYLIC ACID 3-DIMETHYLAMIDE-4'-HYDROXYAMIDE</td>
      <td>DOPFUKKMSDUVTQ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08975</td>
      <td>Florantyrone</td>
      <td>QOBAOSCOLAGPKI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07005</td>
      <td>D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide</td>
      <td>VZFTWWJAUZOJDH-MOPGFXCFSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08927</td>
      <td>Amperozide</td>
      <td>NNAIYOXJNVGUOM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB09075</td>
      <td>Edoxaban</td>
      <td>HGVDHZBSSITLCT-JLJPHGGASA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB09053</td>
      <td>Ibrutinib</td>
      <td>XYFPWWZEPKGCCK-GOSISDBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12388</td>
      <td>Evocalcet</td>
      <td>RZNUIYPHQFXBAN-XLIONFOSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07294</td>
      <td>3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid</td>
      <td>AANFHDFOMFRLLR-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08731</td>
      <td>2-[(1R)-2-carboxy-1-(naphthalen-1-ylmethyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid</td>
      <td>GPOKTQCDBPECSS-MRXNPFEDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00637</td>
      <td>Astemizole</td>
      <td>GXDALQBWZGODGZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12669</td>
      <td>4SC-203</td>
      <td>MAFACRSJGNJHCF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB02723</td>
      <td>4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide</td>
      <td>DHTSUHWLPAEEQB-OALUTQOASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00699</td>
      <td>Nicergoline</td>
      <td>YSEXMKHXIOCEJA-FVFQAYNVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB08827</td>
      <td>Lomitapide</td>
      <td>MBBCVAKAJPKAKM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB12659</td>
      <td>SJ-733</td>
      <td>VKCPFWKTFZAOTO-LEWJYISDSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12149</td>
      <td>S-3304</td>
      <td>YWCLDDLVLSQGSZ-JOCHJYFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12658</td>
      <td>AFN-1252</td>
      <td>QXTWSUQCXCWEHF-JXMROGBWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB11950</td>
      <td>Teneligliptin</td>
      <td>WGRQANOPCQRCME-PMACEKPBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB07325</td>
      <td>N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE</td>
      <td>VCOKUBHAJVTVNG-FMIVXFBMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12128</td>
      <td>Ulimorelin</td>
      <td>WGYPAJVJMXQXTR-ABNZCKJZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08521</td>
      <td>4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE</td>
      <td>CDMGBJANTYXAIV-HHHXNRCGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB02673</td>
      <td>(4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium</td>
      <td>VLGAHTYYCHWLNI-BHRZLAGCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB12504</td>
      <td>JNJ-40346527</td>
      <td>BNVPFDRNGHMRJS-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB11870</td>
      <td>RG-4733</td>
      <td>OJPLJFIFUQPSJR-INIZCTEOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB08444</td>
      <td>3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile</td>
      <td>YYGZQXRLQMFHDH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB15177</td>
      <td>VX-659</td>
      <td>IGEOJNMYRZUKIK-IBGZPJMESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13022</td>
      <td>LY-2874455</td>
      <td>GKJCVYLDJWTWQU-CXLRFSCWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB01200</td>
      <td>Bromocriptine</td>
      <td>OZVBMTJYIDMWIL-AYFBDAFISA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB06237</td>
      <td>Avanafil</td>
      <td>WEAJZXNPAWBCOA-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB05038</td>
      <td>Anatibant</td>
      <td>XUHBBTKJWIBQMY-MHZLTWQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB01200</td>
      <td>Bromocriptine</td>
      <td>OZVBMTJYIDMWIL-AYFBDAFISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB15035</td>
      <td>Zanubrutinib</td>
      <td>RNOAOAWBMHREKO-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB14989</td>
      <td>Umbralisib</td>
      <td>IUVCFHHAEHNCFT-INIZCTEOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13126</td>
      <td>BMS-986115</td>
      <td>SRJNRAQUSAVENA-GSHUGGBRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03788</td>
      <td>GC-24</td>
      <td>JYHIGYLGYNCMGI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB04452</td>
      <td>Aminoquinuride</td>
      <td>HOUSDILKOJMENG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12858</td>
      <td>LY-377604</td>
      <td>RBSGUQYXRDKPAE-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB15168</td>
      <td>Cilofexor</td>
      <td>KZSKGLFYQAYZCO-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12854</td>
      <td>BMS-908662</td>
      <td>MMNNTJYFHUDSKL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03325</td>
      <td>Tyrosyladenylate</td>
      <td>MJZAZMKENKZBAJ-QTOWJTHWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13104</td>
      <td>X-396</td>
      <td>ONPGOSVDVDPBCY-CQSZACIVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB15163</td>
      <td>Selatogrel</td>
      <td>FYXHWMQPCJOJCH-GMAHTHKFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB14946</td>
      <td>PCO-371</td>
      <td>LDZJFVOUPUFOHX-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB15023</td>
      <td>BMS-791826</td>
      <td>DZBKAUMYTFPJIS-QHCPKHFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB05552</td>
      <td>TG100-115</td>
      <td>UJIAQDJKSXQLIT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB04378</td>
      <td>3-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide</td>
      <td>APJAEXGNDLFGPD-AWCRTANDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB00137</td>
      <td>Lutein</td>
      <td>KBPHJBAIARWVSC-RGZFRNHPSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB01259</td>
      <td>Lapatinib</td>
      <td>BCFGMOOMADDAQU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB01698</td>
      <td>Rutin</td>
      <td>IKGXIBQEEMLURG-NVPNHPEKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB06448</td>
      <td>Lonafarnib</td>
      <td>DHMTURDWPRKSOA-RUZDIDTESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13016</td>
      <td>LY-2300559</td>
      <td>DWQVYDLTPMGYNE-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00984</td>
      <td>Nandrolone phenpropionate</td>
      <td>UBWXUGDQUBIEIZ-QNTYDACNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB04432</td>
      <td>ZK-805623</td>
      <td>ZXIHYCYAQUQHSG-UHFFFAOYSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12885</td>
      <td>CF-102</td>
      <td>IPSYPUKKXMNCNQ-PFHKOEEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB04011</td>
      <td>2'-(4-Dimethylaminophenyl)-5-(4-Methyl-1-Piperazinyl)-2,5'-Bi-Benzimidazole</td>
      <td>VMCOQLKKSNQANE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13490</td>
      <td>Hidrosmin</td>
      <td>XYFLWVOTXWXNAM-WTNNCJBMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB15232</td>
      <td>Telaglenastat</td>
      <td>PRAAPINBUWJLGA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00246</td>
      <td>Ziprasidone</td>
      <td>MVWVFYHBGMAFLY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB04190</td>
      <td>Inhibitor Bea425</td>
      <td>AHAVBKNGKPWROK-UMFPTGFGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03268</td>
      <td>RU82197</td>
      <td>WKTQBTSOHBKBRW-VMPREFPWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB06420</td>
      <td>Annamycin</td>
      <td>CIDNKDMVSINJCG-GKXONYSUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00203</td>
      <td>Sildenafil</td>
      <td>BNRNXUUZRGQAQC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12910</td>
      <td>Emicerfont</td>
      <td>JFHJGXQFESYQGY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB06595</td>
      <td>Midostaurin</td>
      <td>BMGQWWVMWDBQGC-IIFHNQTCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB06367</td>
      <td>Relacatib</td>
      <td>BWYBBMQLUKXECQ-GIVPXCGWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB00932</td>
      <td>Tipranavir</td>
      <td>SUJUHGSWHZTSEU-FYBSXPHGSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13653</td>
      <td>Lorcainide</td>
      <td>XHOJAWVAWFHGHL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB14541</td>
      <td>Hydrocortisone cypionate</td>
      <td>DLVOSEUFIRPIRM-KAQKJVHQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB05678</td>
      <td>SLx-4090</td>
      <td>AZUIUVJESCFSLJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB15197</td>
      <td>RSV-604</td>
      <td>MTPVBMVUENFFLL-HXUWFJFHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB12794</td>
      <td>p-Quaterphenyl</td>
      <td>GPRIERYVMZVKTC-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00398</td>
      <td>Sorafenib</td>
      <td>MLDQJTXFUGDVEO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13676</td>
      <td>Mosapramine</td>
      <td>PXUIZULXJVRBPC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB14870</td>
      <td>PF-5190457</td>
      <td>ZIUDADZJCKGWKR-AREMUKBSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13685</td>
      <td>Quingestanol</td>
      <td>PCJFRMOEZQQSAX-AIOSZGMZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB01879</td>
      <td>(S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid</td>
      <td>JOAALZBSMWLOPQ-LJAQVGFWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB06295</td>
      <td>Pramiconazole</td>
      <td>AEKNYBWUEYNWMJ-QWOOXDRHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB01946</td>
      <td>3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione</td>
      <td>UQHKJRCFSLMWIA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB14878</td>
      <td>Liafensine</td>
      <td>VCIBGDSRPUOBOG-QFIPXVFZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03446</td>
      <td>N-Benzyl-3-(alpha-D-galactopyranosyloxy)benzamide</td>
      <td>FSMWGHKWKYCPKE-QTVCLEQKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB15197</td>
      <td>RSV-604</td>
      <td>MTPVBMVUENFFLL-HXUWFJFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB12978</td>
      <td>Pexidartinib</td>
      <td>JGWRKYUXBBNENE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03701</td>
      <td>Vanoxerine</td>
      <td>NAUWTFJOPJWYOT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB04715</td>
      <td>IMIDAZOPYRIDAZIN 1</td>
      <td>IVUBNTNWKIPCPS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>1R42</td>
      <td>DB00320</td>
      <td>Dihydroergotamine</td>
      <td>LUZRJRNZXALNLM-JGRZULCMSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB14859</td>
      <td>Fosifloxuridine nafalbenamide</td>
      <td>BIOWRMNRHMERIO-ZVAHOJSLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03678</td>
      <td>(6,7-Difluoro-Quinazolin-4-Yl)-(1-Methyl-2,2-Diphenyl-Ethyl)-Amine</td>
      <td>WVGZKPGUHOZIJQ-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB01501</td>
      <td>Difenoxin</td>
      <td>UFIVBRCCIRTJTN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13939</td>
      <td>RAD-140</td>
      <td>XMBUPPIEVAFYHO-KPZWWZAWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB06755</td>
      <td>Beta carotene</td>
      <td>OENHQHLEOONYIE-JLTXGRSLSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB06350</td>
      <td>Elinogrel</td>
      <td>LGSDFTPAICUONK-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12817</td>
      <td>Zoliflodacin</td>
      <td>ZSWMIFNWDQEXDT-ZESJGQACSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB15346</td>
      <td>GLPG-1205</td>
      <td>IRBAWVGZNJIROV-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB13093</td>
      <td>TAK-593</td>
      <td>DZFZXPPHBWCXPQ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB13941</td>
      <td>Piperaquine</td>
      <td>UCRHFBCYFMIWHC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB15431</td>
      <td>M-2698</td>
      <td>HXAUJHZZPCBFPN-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12808</td>
      <td>Trifarotene</td>
      <td>MFBCDACCJCDGBA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00496</td>
      <td>Darifenacin</td>
      <td>HXGBXQDTNZMWGS-RUZDIDTESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB00598</td>
      <td>Labetalol</td>
      <td>SGUAFYQXFOLMHL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB15305</td>
      <td>Risdiplam</td>
      <td>ASKZRYGFUPSJPN-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB12805</td>
      <td>Ataciguat</td>
      <td>PQHLRGARXNPFCF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6LZG</td>
      <td>DB04591</td>
      <td>N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE</td>
      <td>VYJOAYZRCNHDNG-GOSISDBHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>1R42</td>
      <td>DB04016</td>
      <td>2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid</td>
      <td>XUJQPDQURBZEGJ-KXQOOQHDSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.8</td>
      <td>6CS2</td>
      <td>DB03572</td>
      <td>FR230513</td>
      <td>URGFTPMACWKJKU-OAHLLOKOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13954</td>
      <td>Estradiol cypionate</td>
      <td>UOACKFBJUYNSLK-XRKIENNPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB15193</td>
      <td>BMS-955176</td>
      <td>XDMUFNNPLXHNKA-ZTESCHFWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13993</td>
      <td>MRK-409</td>
      <td>GOIFCXRIFSYPFG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB03351</td>
      <td>Sri-9439</td>
      <td>KMSATRJZEXNGDP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB02226</td>
      <td>3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium</td>
      <td>NAARZDJZGYBXKL-UHFFFAOYSA-O</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB05015</td>
      <td>Belinostat</td>
      <td>NCNRHFGMJRPRSK-MDZDMXLPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB01167</td>
      <td>Itraconazole</td>
      <td>VHVPQPYKVGDNFY-ZPGVKDDISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB05913</td>
      <td>OSI-930</td>
      <td>FGTCROZDHDSNIO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06624</td>
      <td>Taranabant</td>
      <td>QLYKJCMUNUWAGO-GAJHUEQPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07131</td>
      <td>(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide</td>
      <td>DOTBZTLJSXFKCP-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08772</td>
      <td>3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2-BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID</td>
      <td>BCSVCWVQNOXFGL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB05936</td>
      <td>CVT-6883</td>
      <td>KOYXXLLNCXWUNF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13078</td>
      <td>KOSN-1724</td>
      <td>JAYGOFBXDFAXBW-CYEKYUJNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06608</td>
      <td>Tafenoquine</td>
      <td>LBHLFPGPEGDCJG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06605</td>
      <td>Apixaban</td>
      <td>QNZCBYKSOIHPEH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB00820</td>
      <td>Tadalafil</td>
      <td>WOXKDUGGOYFFRN-IIBYNOLFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB04764</td>
      <td>[4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE</td>
      <td>CCLHROFBSWWOQO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB04071</td>
      <td>Cpad</td>
      <td>LFERELMXERXKKQ-KMXXXSRASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06603</td>
      <td>Panobinostat</td>
      <td>FPOHNWQLNRZRFC-ZHACJKMWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB01251</td>
      <td>Gliquidone</td>
      <td>LLJFMFZYVVLQKT-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07809</td>
      <td>4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE</td>
      <td>MBJYEMUMDMGQQC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB08073</td>
      <td>(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE</td>
      <td>YWTBGJGMTBHQTM-IBGZPJMESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12022</td>
      <td>Evatanepag</td>
      <td>WOHRHWDYFNWPNG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB15190</td>
      <td>GLPG-0259</td>
      <td>YBFGSJUVEOYPIS-OALUTQOASA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB04727</td>
      <td>N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA</td>
      <td>FGZIONRFHVNRJB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB12385</td>
      <td>10-hydroxycamptothecin</td>
      <td>HAWSQZCWOQZXHI-FQEVSTJZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB06543</td>
      <td>Astaxanthin</td>
      <td>MQZIGYBFDRPAKN-UWFIBFSHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08911</td>
      <td>Trametinib</td>
      <td>LIRYPHYGHXZJBZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12306</td>
      <td>Cipargamin</td>
      <td>CKLPLPZSUQEDRT-WPCRTTGESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07203</td>
      <td>6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE</td>
      <td>OUEGMEMDEAOAEG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB12134</td>
      <td>Gepotidacin</td>
      <td>PZFAZQUREQIODZ-LJQANCHMSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12253</td>
      <td>GDC-0810</td>
      <td>BURHGPHDEVGCEZ-KJGLQBJMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB03020</td>
      <td>5-Beta-D-Ribofuranosylnicotinamide Adenine Dinucleotide</td>
      <td>UINNILASBHZOTM-KMXXXSRASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12147</td>
      <td>Erdafitinib</td>
      <td>OLAHOMJCDNXHFI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB02827</td>
      <td>7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid</td>
      <td>MDYIGSPVMWSFEZ-JTQLQIEISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06267</td>
      <td>Udenafil</td>
      <td>IYFNEFQTYQPVOC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB09280</td>
      <td>Lumacaftor</td>
      <td>UFSKUSARDNFIRC-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB15362</td>
      <td>LSZ-102</td>
      <td>SJXNPGGVGZXKKI-NYYWCZLTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB12225</td>
      <td>Beclabuvir</td>
      <td>ZTTKEBYSXUCBSE-QDFUAKMASA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07263</td>
      <td>[{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid</td>
      <td>WDTMVBQZDFMOIK-GOSISDBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12221</td>
      <td>Canrenone</td>
      <td>UJVLDDZCTMKXJK-WNHSNXHDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06281</td>
      <td>Torcetrapib</td>
      <td>CMSGWTNRGKRWGS-NQIIRXRSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB15345</td>
      <td>GSK-945237</td>
      <td>SRICOHRDRMZREQ-MRXNPFEDSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB15333</td>
      <td>AZD-1386</td>
      <td>FPGNKXCEPARJDI-ZDUSSCGKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB07977</td>
      <td>3-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)THIOPHENE-2-CARBOXYLIC ACID</td>
      <td>CGNHUSCKOHDSMR-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB12207</td>
      <td>Verdinexor</td>
      <td>OPAKEJZFFCECPN-XQRVVYSFSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB01051</td>
      <td>Novobiocin</td>
      <td>YJQPYGGHQPGBLI-KGSXXDOSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB15292</td>
      <td>Foliglurax</td>
      <td>ZTEDNASHAWNBKQ-NCELDCMTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB07970</td>
      <td>5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide</td>
      <td>SAAYRHKJHDIDPH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB09268</td>
      <td>Picosulfuric acid</td>
      <td>UJIDKYTZIQTXPM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07287</td>
      <td>2-(2,4-DICHLOROPHENOXY)-5-(PYRIDIN-2-YLMETHYL)PHENOL</td>
      <td>AOVDSWPGWPRTSR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB04609</td>
      <td>INHIBITOR Q8467 OF DUPONT MERCK</td>
      <td>HFLCERPZYCWLSZ-VKONIRKNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB07966</td>
      <td>[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile</td>
      <td>NVMCVWOODOWOLT-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB02432</td>
      <td>RU90395</td>
      <td>RLLAUERCSKPFGD-VMPREFPWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB01126</td>
      <td>Dutasteride</td>
      <td>JWJOTENAMICLJG-QWBYCMEYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB15265</td>
      <td>USL-311</td>
      <td>XNUNVQKARNSSEO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB09050</td>
      <td>Ceftolozane</td>
      <td>JHFNIHVVXRKLEF-DCZLAGFPSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06515</td>
      <td>Resiniferatoxin</td>
      <td>DSDNAKHZNJAGHN-MXTYGGKSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13308</td>
      <td>Oxametacin</td>
      <td>AJRNYCDWNITGHF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13327</td>
      <td>Picotamide</td>
      <td>KYWCWBXGRWWINE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB11275</td>
      <td>Epicriptine</td>
      <td>SBFXHXZNBNFPHV-PXXBSISHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB11273</td>
      <td>Dihydroergocornine</td>
      <td>SEALOBQTUQIVGU-QNIJNHAOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13397</td>
      <td>Prenoxdiazine</td>
      <td>PXZDWASDNFWKSD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13927</td>
      <td>anle138b</td>
      <td>RCQIIBJSUWYYFU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB07360</td>
      <td>1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea</td>
      <td>JJHXPDTVQKWKHA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13919</td>
      <td>Candesartan</td>
      <td>HTQMVQVXFRQIKW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB15257</td>
      <td>Milademetan</td>
      <td>RYAYYVTWKAOAJF-QISPRATLSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB02483</td>
      <td>Etheno-Nad</td>
      <td>JCDBQDNBEQHDHK-BSLNIGMPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06519</td>
      <td>Edaglitazone</td>
      <td>HAAXAFNSRADSMK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13471</td>
      <td>Nalfurafine</td>
      <td>XGZZHZMWIXFATA-UEZBDDGYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06446</td>
      <td>Dotarizine</td>
      <td>LRMJAFKKJLRDLE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB00862</td>
      <td>Vardenafil</td>
      <td>SECKRCOLJRRGGV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB01767</td>
      <td>Hemi-Babim</td>
      <td>KKJYVDXDZURHMA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB08010</td>
      <td>(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime</td>
      <td>DDHASJXGNUWZTM-ZLEWNXFRSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB09488</td>
      <td>Acrivastine</td>
      <td>PWACSDKDOHSSQD-IUTFFREVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12282</td>
      <td>Defactinib</td>
      <td>FWLMVFUGMHIOAA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB02833</td>
      <td>[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine</td>
      <td>DYTKVFHLKPDNRW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12275</td>
      <td>Seviteronel</td>
      <td>ZBRAJOQFSNYJMF-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB01721</td>
      <td>Analogue of Indinavir Drug</td>
      <td>MJIRDPUZGGHJMX-OIVSQUILSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB07247</td>
      <td>[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA</td>
      <td>SRPOHNDQBDHONJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06229</td>
      <td>Ocaperidone</td>
      <td>ZZQNEJILGNNOEP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB12121</td>
      <td>Entospletinib</td>
      <td>XSMSNFMDVXXHGJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB11656</td>
      <td>Rebamipide</td>
      <td>ALLWOAVDORUJLA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07107</td>
      <td>(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE</td>
      <td>SGHXFHRRWFLILP-XJDXJNMNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07965</td>
      <td>6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile</td>
      <td>OGODDSLNRULSMM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB11911</td>
      <td>Galunisertib</td>
      <td>IVRXNBXKWIJUQB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07618</td>
      <td>2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE</td>
      <td>AITZHKQVQNLKHI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07015</td>
      <td>(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine</td>
      <td>XDSKICAQKGYYJF-OLZOCXBDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB11793</td>
      <td>Niraparib</td>
      <td>PCHKPVIQAHNQLW-CQSZACIVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07549</td>
      <td>2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE</td>
      <td>WOYBPRBUPLYTPY-UHFFFAOYSA-P</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08569</td>
      <td>3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE</td>
      <td>VLPMRZSKJUTRBQ-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08304</td>
      <td>(3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide</td>
      <td>QZBQVXXESPXFPZ-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB02014</td>
      <td>5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid</td>
      <td>QKHWJUMLYAYZFS-ONEGZZNKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB02616</td>
      <td>FR117016</td>
      <td>CKJGKHXCUDWFDC-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB12580</td>
      <td>Tradipitant</td>
      <td>CAVRKWRKTNINFF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB04859</td>
      <td>Zanapezil</td>
      <td>PMBLXLOXUGVTGB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12836</td>
      <td>Grapiprant</td>
      <td>HZVLFTCYCLXTGV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08493</td>
      <td>5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID</td>
      <td>AKWKBACKRMYPRV-NQIIRXRSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB02915</td>
      <td>4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine</td>
      <td>MEZFDQUDLQCVNX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07692</td>
      <td>1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine</td>
      <td>SHWNKRPMUBFWKE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB07549</td>
      <td>2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE</td>
      <td>WOYBPRBUPLYTPY-UHFFFAOYSA-P</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB00398</td>
      <td>Sorafenib</td>
      <td>MLDQJTXFUGDVEO-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB01659</td>
      <td>3-(1,10-Phenanthrol-2-Yl)-L-Alanine</td>
      <td>LODBCIBKOKOGNL-LBPRGKRZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB15075</td>
      <td>4-demethyl-4-cholesteryloxycarbonylpenclomedine</td>
      <td>ZJUUIXYKTPSIOH-LEZJFEBPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08562</td>
      <td>4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID</td>
      <td>FTXJWRRYLLRFMG-MDZDMXLPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB04942</td>
      <td>Tamibarotene</td>
      <td>MUTNCGKQJGXKEM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB11907</td>
      <td>Rociletinib</td>
      <td>HUFOZJXAKZVRNJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB01573</td>
      <td>Benzylmorphine</td>
      <td>RDJGWRFTDZZXSM-RNWLQCGYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB05039</td>
      <td>Indacaterol</td>
      <td>QZZUEBNBZAPZLX-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12655</td>
      <td>Patidegib</td>
      <td>HZLFFNCLTRVYJG-WWGOJCOQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB11878</td>
      <td>Filibuvir</td>
      <td>SLVAPEZTBDBAPI-GDLZYMKVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB14801</td>
      <td>Lanifibranor</td>
      <td>OQDQIFQRNZIEEJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB14802</td>
      <td>ONO-2952</td>
      <td>ZBQMTQGDBFZUBG-NRFANRHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12888</td>
      <td>Ezutromid</td>
      <td>KSGCNXAZROJSNW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB15009</td>
      <td>PF-04937319</td>
      <td>MASKQITXHVYVFL-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB01340</td>
      <td>Cilazapril</td>
      <td>HHHKFGXWKKUNCY-FHWLQOOXSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12645</td>
      <td>Givinostat</td>
      <td>YALNUENQHAQXEA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12644</td>
      <td>AZD-2066</td>
      <td>SXWHYTICXCLKDG-GFCCVEGCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07717</td>
      <td>(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE</td>
      <td>AJODXHGZHBERGJ-JLYQOUBASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB01092</td>
      <td>Ouabain</td>
      <td>LPMXVESGRSUGHW-HBYQJFLCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB15013</td>
      <td>TAK-243</td>
      <td>KJDAGXLMHXUAGV-DGWLBADLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12627</td>
      <td>GSK-1292263</td>
      <td>AYJRTVVIBJSSKN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB05220</td>
      <td>Alisertib</td>
      <td>ZLHFILGSQDJULK-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12929</td>
      <td>JNJ-39220675</td>
      <td>IQOWHZHNGJXGHG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB03802</td>
      <td>1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol</td>
      <td>ZGHFWBDHZZKWSI-LITSAYRRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06969</td>
      <td>2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide</td>
      <td>WJUNQSYQHHIVFX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08345</td>
      <td>4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE</td>
      <td>IWUUKHQIKFHWIW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB01261</td>
      <td>Sitagliptin</td>
      <td>MFFMDFFZMYYVKS-SECBINFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB14676</td>
      <td>Fagrocorat</td>
      <td>QJJBNCHSWFGXML-KEKPKEOLSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB14918</td>
      <td>Branaplam</td>
      <td>STWTUEAWRAIWJG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6lu7</td>
      <td>DB03231</td>
      <td>"3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide"</td>
      <td>IXDQOBDHBWEZOH-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB11816</td>
      <td>Omecamtiv Mecarbil</td>
      <td>RFUBTTPMWSKEIW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB05575</td>
      <td>Motesanib</td>
      <td>RAHBGWKEPAQNFF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB14898</td>
      <td>Retagliptin</td>
      <td>WIIAMRXFUJLYEF-SNVBAGLBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12511</td>
      <td>Imiglitazar</td>
      <td>ULVDFHLHKNJICZ-QCWLDUFUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12729</td>
      <td>ASP-3026</td>
      <td>MGGBYMDAPCCKCT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB12511</td>
      <td>Imiglitazar</td>
      <td>ULVDFHLHKNJICZ-QCWLDUFUSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB02629</td>
      <td>Inhibitor Bea403</td>
      <td>LYHLPPXMBKMSSZ-JQFCFGFHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB11701</td>
      <td>Amenamevir</td>
      <td>MNHNIVNAFBSLLX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07685</td>
      <td>4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE</td>
      <td>NMAZGYDYIYLSLJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12500</td>
      <td>Fedratinib</td>
      <td>JOOXLOJCABQBSG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>1R42</td>
      <td>DB02555</td>
      <td>SP4160</td>
      <td>VCXMTWSYQSVWRK-AREMUKBSSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07524</td>
      <td>N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine</td>
      <td>CQFGXDQUQWRXLE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13060</td>
      <td>CEP-37440</td>
      <td>BCSHRERPHLTPEE-NRFANRHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08426</td>
      <td>THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDE</td>
      <td>PLXOQMHGHDZMSX-AWEZNQCLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>1R42</td>
      <td>DB00210</td>
      <td>Adapalene</td>
      <td>LZCDAPDGXCYOEH-UHFFFAOYSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB03480</td>
      <td>Brequinar Analog</td>
      <td>WYKKHJQZENLZID-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB15110</td>
      <td>Onvansertib</td>
      <td>QHLVBNKYJGBCQJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>1R42</td>
      <td>DB00762</td>
      <td>Irinotecan</td>
      <td>UWKQSNNFCGGAFS-XIFFEERXSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08220</td>
      <td>(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid</td>
      <td>RPNNXCYIESWDSC-JRZBRKEGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08437</td>
      <td>Puromycin</td>
      <td>RXWNCPJZOCPEPQ-NVWDDTSBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB11966</td>
      <td>BMS-986094</td>
      <td>YFXGICNMLCGLHJ-RSKRLRQZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12999</td>
      <td>MK-6186</td>
      <td>FZBAOOQVQXATRL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08657</td>
      <td>2-(4-(2-((3-(5-(PYRIDIN-2-YLTHIO)THIAZOL-2-YL)UREIDO)METHYL)-1H-IMIDAZOL-4-YL)PHENOXY)ACETIC ACID</td>
      <td>SSXCWVOQWRUMGN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB04881</td>
      <td>Elacridar</td>
      <td>OSFCMRGOZNQUSW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB11718</td>
      <td>Encorafenib</td>
      <td>CMJCXYNUCSMDBY-ZDUSSCGKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB06666</td>
      <td>Lixivaptan</td>
      <td>PPHTXRNHTVLQED-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07117</td>
      <td>5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE</td>
      <td>FMKQJGOROFNCGM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB03367</td>
      <td>PF-00356231</td>
      <td>VMTJQZUZINLEKC-JOCHJYFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07058</td>
      <td>5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione</td>
      <td>QBVJMUOTMRYUKR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07689</td>
      <td>METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE</td>
      <td>NYNAFINLHQEHKU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07786</td>
      <td>1-((1R,2S)-1-{2-[2-(4-CHLOROPHENYL)-1,3-BENZOXAZOL-7-YL]ETHYL}-2-HYDROXYPROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE</td>
      <td>SMFRBBHLVBWHGB-DJJJIMSYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB00973</td>
      <td>Ezetimibe</td>
      <td>OLNTVTPDXPETLC-XPWALMASSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB07664</td>
      <td>5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE</td>
      <td>ARIOBGGRZJITQX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB15106</td>
      <td>Surufatinib</td>
      <td>TTZSNFLLYPYKIL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB08697</td>
      <td>4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide</td>
      <td>JDYIYIRPQKMWMM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB12719</td>
      <td>Turofexorate isopropyl</td>
      <td>INASOKQDNHHMRE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6LZG</td>
      <td>DB11804</td>
      <td>AZD-5672</td>
      <td>SCXSQUUTGCWHFU-WJOKGBTCSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB14899</td>
      <td>Tavapadon</td>
      <td>AKQXQLUNFKDZBN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.7</td>
      <td>6CS2</td>
      <td>DB13055</td>
      <td>Oteseconazole</td>
      <td>IDUYJRXRDSPPRC-NRFANRHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06246</td>
      <td>Exisulind</td>
      <td>MVGSNCBCUWPVDA-MFOYZWKCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07296</td>
      <td>(5Z)-3-(4-CHLOROPHENYL)-4-HYDROXY-5-(1-NAPHTHYLMETHYLENE)FURAN-2(5H)-ONE</td>
      <td>PLGHLEBIWUQEPR-PDGQHHTCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB14943</td>
      <td>LGH-447</td>
      <td>VRQXRVAKPDCRCI-ZNMIVQPWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB02331</td>
      <td>(2s)-2-[(5-Benzofuran-2-Yl-Thiophen-2-Ylmethyl)-(2,4-Dichloro-Benzoyl)-Amino]-3-Phenyl-Propionic Acid</td>
      <td>YBULOUKTPCHXAL-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB11818</td>
      <td>Retosiban</td>
      <td>PLVGDGRBPMVYPB-FDUHJNRSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB14916</td>
      <td>Selonsertib</td>
      <td>YIDDLAAKOYYGJG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB14934</td>
      <td>GDC-0927</td>
      <td>KJAAPZIFCQQQKX-NDEPHWFRSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06257</td>
      <td>HE-2200</td>
      <td>OEVZKEVBDIDVOI-YSZCXEEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB14840</td>
      <td>Ripretinib</td>
      <td>CEFJVGZHQAGLHS-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07612</td>
      <td>6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE</td>
      <td>XQKJVNGGVLHNLA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07613</td>
      <td>3-phenyl-5-(1H-pyrazol-3-yl)isoxazole</td>
      <td>SRSSTOPJERVMRZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB13788</td>
      <td>Chlorbenzoxamine</td>
      <td>VEVSKUJZSMGTMM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB11863</td>
      <td>Alvelestat</td>
      <td>QNQZWEGMKJBHEM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB11794</td>
      <td>Berzosertib</td>
      <td>JZCWLJDSIRUGIN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB07307</td>
      <td>N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide</td>
      <td>GQXMJOSCBRZMKE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07622</td>
      <td>1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA</td>
      <td>KRKQVGZXTNLQSV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB13767</td>
      <td>Vorozole</td>
      <td>XLMPPFTZALNBFS-INIZCTEOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB12128</td>
      <td>Ulimorelin</td>
      <td>WGYPAJVJMXQXTR-ABNZCKJZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04616</td>
      <td>TACRINE(8)-4-AMINOQUINOLINE</td>
      <td>UNVOAAWEEGAXTN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB11805</td>
      <td>Saracatinib</td>
      <td>OUKYUETWWIPKQR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB01685</td>
      <td>Topiroxostat</td>
      <td>UBVZQGOVTLIHLH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB01640</td>
      <td>(5r)-6-(4-{[2-(3-Iodobenzyl)-3-Oxocyclohex-1-En-1-Yl]Amino}Phenyl)-5-Methyl-4,5-Dihydropyridazin-3(2h)-One</td>
      <td>QNURTFDBHAQRSI-OAHLLOKOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB00875</td>
      <td>Flupentixol</td>
      <td>NJMYODHXAKYRHW-DVZOWYKESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB11957</td>
      <td>Idalopirdine</td>
      <td>YBAWYTYNMZWMMJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB05511</td>
      <td>Piclidenoson</td>
      <td>HUJXGQILHAUCCV-MOROJQBDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB11464</td>
      <td>Sulfaquinoxaline</td>
      <td>NHZLNPMOSADWGC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB15108</td>
      <td>Tipranavir C-14</td>
      <td>SUJUHGSWHZTSEU-MWQIXQBFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12015</td>
      <td>Alpelisib</td>
      <td>STUWGJZDJHPWGZ-LBPRGKRZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB11703</td>
      <td>Acalabrutinib</td>
      <td>WDENQIQQYWYTPO-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB00715</td>
      <td>Paroxetine</td>
      <td>AHOUBRCZNHFOSL-YOEHRIQHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB14067</td>
      <td>Dofequidar</td>
      <td>KLWUUPVJTLHYIM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB15085</td>
      <td>Fulacimstat</td>
      <td>JDARDSVOVYVQST-MRXNPFEDSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04792</td>
      <td>2,5-O,O-BIS-{4',4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL</td>
      <td>CDEVHSIVANGYRI-XMTFNYHQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB11694</td>
      <td>Ilorasertib</td>
      <td>WPHKIQPVPYJNAX-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB01678</td>
      <td>RU84687</td>
      <td>SAFPHFWYRLLBFO-NSOVKSMOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB11681</td>
      <td>Tofimilast</td>
      <td>DHCOPPHTVOXDKU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB02241</td>
      <td>8-Benzyl-2-Hydroperoxy-2-(4-Hydroxy-Benzyl)-6-(4-Hydroxy-Phenyl)-2h-Imidazo[1,2-a]Pyrazin-3-One</td>
      <td>HOSWCJDTHOAORT-SANMLTNESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB15133</td>
      <td>Tepotinib</td>
      <td>AHYMHWXQRWRBKT-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB15132</td>
      <td>AZD-8165</td>
      <td>YUHNXUAATAMVKD-PZJWPPBQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06295</td>
      <td>Pramiconazole</td>
      <td>AEKNYBWUEYNWMJ-QWOOXDRHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07792</td>
      <td>(S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE</td>
      <td>VUKPNWLGSLOHIF-AWEZNQCLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04790</td>
      <td>2,5-bis-O-{3-[amino(imino)methyl]phenyl}-1,4:3,6-dianhydro-D-glucitol</td>
      <td>IBIUTOFGXGGVKQ-XMTFNYHQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB11697</td>
      <td>Pacritinib</td>
      <td>HWXVIOGONBBTBY-ONEGZZNKSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB14676</td>
      <td>Fagrocorat</td>
      <td>QJJBNCHSWFGXML-KEKPKEOLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04849</td>
      <td>Cediranib</td>
      <td>XXJWYDDUDKYVKI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB15039</td>
      <td>ITI-214</td>
      <td>BBIPVJCGIASXJB-PKTZIBPZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB03010</td>
      <td>Patupilone</td>
      <td>QXRSDHAAWVKZLJ-PVYNADRNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07595</td>
      <td>(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE</td>
      <td>WSIQKQLAGWVKSL-UHFFFAOYSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB05075</td>
      <td>TG-100801</td>
      <td>JMGXJHWTVBGOKG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12122</td>
      <td>Figopitant</td>
      <td>HUTHJVYJUPXHDF-DEOSSOPVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB05220</td>
      <td>Alisertib</td>
      <td>ZLHFILGSQDJULK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07340</td>
      <td>N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine</td>
      <td>ZFLJHSQHILSNCM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07584</td>
      <td>N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine</td>
      <td>OKGCSZUKOGMZAL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB13874</td>
      <td>Enasidenib</td>
      <td>DYLUUSLLRIQKOE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07568</td>
      <td>(2S)-2-[(2,1,3-BENZOTHIADIAZOL-4-YLSULFONYL)AMINO]-2-PHENYL-N-PYRIDIN-4-YLACETAMIDE</td>
      <td>ADRNPUSZBRQDBG-KRWDZBQOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07753</td>
      <td>3',5'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID</td>
      <td>VCEFNMHMLWBFNV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB07550</td>
      <td>2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE</td>
      <td>ZIGSBBKEPNQXRG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07848</td>
      <td>5-Chloro-N-{(3S)-1-[(2S)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1H-indole-2-sulfonamide</td>
      <td>BHNMMFGOJRIAEZ-LRDDRELGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB05414</td>
      <td>Pipendoxifene</td>
      <td>JICOGKJOQXTAIP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB07382</td>
      <td>N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine</td>
      <td>WJNBSTLIALIIEW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12064</td>
      <td>BMS-777607</td>
      <td>VNBRGSXVFBYQNN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB05416</td>
      <td>Cardarine</td>
      <td>YDBLKRPLXZNVNB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB14716</td>
      <td>Clonazolam</td>
      <td>XJRGLCAWBRZUFC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB13947</td>
      <td>Testosterone enantate benzilic acid hydrazone</td>
      <td>PTVXYACXDYZNID-JKXGKYMWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB15224</td>
      <td>Lisavanbulin</td>
      <td>NIPZLALJRAHABJ-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12055</td>
      <td>MK-0767</td>
      <td>ORZMUVMQJPGFOM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06137</td>
      <td>KX-01</td>
      <td>HUNGUWOZPQBXGX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB14995</td>
      <td>NP-G2-044</td>
      <td>XLLRLAABUFOJPC-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB15245</td>
      <td>Olorofim</td>
      <td>SUFPWYYDCOKDLL-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB13552</td>
      <td>Trifluperidol</td>
      <td>GPMXUUPHFNMNDH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12465</td>
      <td>Ketanserin</td>
      <td>FPCCSQOGAWCVBH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07014</td>
      <td>2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole</td>
      <td>TUTZKAQTSPMEBI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08770</td>
      <td>4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol</td>
      <td>PWTBZOIUWZOPFT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08350</td>
      <td>5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE</td>
      <td>GYQRHHQPEMOLKH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB00820</td>
      <td>Tadalafil</td>
      <td>WOXKDUGGOYFFRN-IIBYNOLFSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08092</td>
      <td>3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide</td>
      <td>VMLSXFMXUNVCSK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB12414</td>
      <td>Usistapide</td>
      <td>WSYALRNYQFNNGP-WJOKGBTCSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12937</td>
      <td>Quercetin-3'-O-phosphate</td>
      <td>UWJBYNLLMAPJMM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB13104</td>
      <td>X-396</td>
      <td>ONPGOSVDVDPBCY-CQSZACIVSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12598</td>
      <td>Nafamostat</td>
      <td>MQQNFDZXWVTQEH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB01940</td>
      <td>Balanol Analog 2</td>
      <td>SQLYTJZXRRDERK-ISKFKSNPSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12622</td>
      <td>Lupeol</td>
      <td>MQYXUWHLBZFQQO-QGTGJCAVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB08358</td>
      <td>2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE</td>
      <td>OWFLADWRSCINST-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06589</td>
      <td>Pazopanib</td>
      <td>CUIHSIWYWATEQL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB08111</td>
      <td>4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol</td>
      <td>ZGJYGQLGSXWEMY-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6lu7</td>
      <td>DB12983</td>
      <td>Phthalocyanine</td>
      <td>IEQIEDJGQAUEQZ-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04204</td>
      <td>[(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid</td>
      <td>SRHSAABKYJDBDV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB00655</td>
      <td>Estrone</td>
      <td>DNXHEGUUPJUMQT-CBZIJGRNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB13158</td>
      <td>Clobetasone</td>
      <td>XXIFVOHLGBURIG-OZCCCYNHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB13164</td>
      <td>Olmutinib</td>
      <td>FDMQDKQUTRLUBU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB00210</td>
      <td>Adapalene</td>
      <td>LZCDAPDGXCYOEH-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08896</td>
      <td>Regorafenib</td>
      <td>FNHKPVJBJVTLMP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB08361</td>
      <td>2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide</td>
      <td>NZNTWOVDIXCHHS-LSDHHAIUSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08052</td>
      <td>1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine</td>
      <td>NVRXTLZYXZNATH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08639</td>
      <td>Dapivirine</td>
      <td>ILAYIAGXTHKHNT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04244</td>
      <td>(2R)-2-(3-Biphenylyl)-N-{(2R)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide</td>
      <td>YCDHZDINQZLSRR-DNQXCXABSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12877</td>
      <td>Oxatomide</td>
      <td>BAINIUMDFURPJM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6lu7</td>
      <td>DB15399</td>
      <td>BMS-754807</td>
      <td>LQVXSNNAFNGRAH-QHCPKHFHSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08383</td>
      <td>4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole</td>
      <td>XBMULXNXJLWLLD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12895</td>
      <td>TD-139</td>
      <td>YGIDGBAHDZEYMT-MQFIMZJJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6lu7</td>
      <td>DB04868</td>
      <td>Nilotinib</td>
      <td>HHZIURLSWUIHRB-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB00796</td>
      <td>Candesartan cilexetil</td>
      <td>GHOSNRCGJFBJIB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08125</td>
      <td>4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE</td>
      <td>BOMPRXSVSIPRDT-PTNGSMBKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB12985</td>
      <td>Quisinostat</td>
      <td>PAWIYAYFNXQGAP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB12571</td>
      <td>Rimacalib</td>
      <td>MYTIJGWONQOOLC-HNNXBMFYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12998</td>
      <td>PF-00217830</td>
      <td>QGNOXTFZOLDODX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>1R42</td>
      <td>DB04330</td>
      <td>Bilh 434</td>
      <td>KNRVCCXHLSHTFW-HGPRPZRGSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08233</td>
      <td>6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE</td>
      <td>RFSDQDHHBKYQOD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB13019</td>
      <td>Henatinib</td>
      <td>MCTXSDCWFQAGFS-UEXNTNOUSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08303</td>
      <td>(3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide</td>
      <td>CUMKMTBOHBENJI-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB13019</td>
      <td>Henatinib</td>
      <td>MCTXSDCWFQAGFS-UEXNTNOUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06731</td>
      <td>Seproxetine</td>
      <td>WIQRCHMSJFFONW-HNNXBMFYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB07065</td>
      <td>5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>AHPKUZJCNHGFQA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB00224</td>
      <td>Indinavir</td>
      <td>CBVCZFGXHXORBI-PXQQMZJSSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB04011</td>
      <td>2'-(4-Dimethylaminophenyl)-5-(4-Methyl-1-Piperazinyl)-2,5'-Bi-Benzimidazole</td>
      <td>VMCOQLKKSNQANE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06732</td>
      <td>beta-Naphthoflavone</td>
      <td>OUGIDAPQYNCXRA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB08708</td>
      <td>N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine</td>
      <td>XYYDXQCAYXOGQT-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12507</td>
      <td>Atecegatran metoxil</td>
      <td>XSNMGLZVFNDDPW-ZWKOTPCHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB02009</td>
      <td>L-756,423</td>
      <td>AOMZDQMIOCTPQP-QHQMVRJISA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB01836</td>
      <td>[4-(6-Chloro-Naphthalene-2-Sulfonyl)-Piperazin-1-Yl]-(3,4,5,6-Tetrahydro-2h-[1,4']Bipyridinyl-4-Yl)-Methanone</td>
      <td>ZLAKCKVFSRSENR-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08154</td>
      <td>3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile</td>
      <td>WHCLIFOVZDANCU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB02008</td>
      <td>1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine</td>
      <td>JHSHXKJSPVHPCJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB03642</td>
      <td>Benzofuran-2-Carboxylic Acid {(S)-3-Methyl-1-[3-Oxo-1-(Pyridin-2-Ylsulfonyl)Azepan-4-Ylcarbamoyl]Butyl}Amide</td>
      <td>VBPPNJCVXGAZDD-PMACEKPBSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB00471</td>
      <td>Montelukast</td>
      <td>UCHDWCPVSPXUMX-TZIWLTJVSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB06630</td>
      <td>Anacetrapib</td>
      <td>MZZLGJHLQGUVPN-HAWMADMCSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08340</td>
      <td>N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE</td>
      <td>LLYYAUZAGCZEKV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07081</td>
      <td>(2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE</td>
      <td>FDEXEPZGMKFCTG-PSASIEDQSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04038</td>
      <td>Ergosterol</td>
      <td>DNVPQKQSNYMLRS-APGDWVJJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB01721</td>
      <td>Analogue of Indinavir Drug</td>
      <td>MJIRDPUZGGHJMX-OIVSQUILSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB06302</td>
      <td>Glesatinib</td>
      <td>YRCHYHRCBXNYNU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06629</td>
      <td>Zibotentan</td>
      <td>FJHHZXWJVIEFGJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12459</td>
      <td>Belotecan</td>
      <td>LNHWXBUNXOXMRL-VWLOTQADSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06983</td>
      <td>(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol</td>
      <td>RBLKWWBHDUBPFN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12666</td>
      <td>Emapunil</td>
      <td>NBMBIEOUVBHEBM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>1R42</td>
      <td>DB03466</td>
      <td>BMS184394</td>
      <td>AYAJZQYENGWICE-QHCPKHFHSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08631</td>
      <td>N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE</td>
      <td>UVSIFVBCHJEYJP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB03696</td>
      <td>Lanosterol</td>
      <td>CAHGCLMLTWQZNJ-BQNIITSRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07256</td>
      <td>3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE</td>
      <td>ZVQZIVCQLFGXFZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB09030</td>
      <td>Vorapaxar</td>
      <td>ZBGXUVOIWDMMJE-QHNZEKIYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB13607</td>
      <td>Picloxydine</td>
      <td>YNCLPFSAZFGQCD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB12297</td>
      <td>GLPG-0187</td>
      <td>CXHCNOMGODVIKB-VWLOTQADSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB04495</td>
      <td>RU81843</td>
      <td>GGPXNASQNUOIPB-NSOVKSMOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07244</td>
      <td>5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE</td>
      <td>SRRWXMSVQYQCRX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB01029</td>
      <td>Irbesartan</td>
      <td>YOSHYTLCDANDAN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB08470</td>
      <td>3-(4-fluorophenyl)-5-phenyl-4H-1,2,4-triazole</td>
      <td>KMGPJKOKSYGMJD-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB08426</td>
      <td>THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDE</td>
      <td>PLXOQMHGHDZMSX-AWEZNQCLSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08418</td>
      <td>(4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate</td>
      <td>LSJKARAMQNGZDF-YOEKFXIASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06944</td>
      <td>N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide</td>
      <td>RIGZCVNCFXYBEG-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB15403</td>
      <td>Ziritaxestat</td>
      <td>REQQVBGILUTQNN-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08423</td>
      <td>[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE</td>
      <td>QKZZJXRGCHXIAI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB09048</td>
      <td>Netupitant</td>
      <td>WAXQNWCZJDTGBU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB14879</td>
      <td>Cefiderocol</td>
      <td>DBPPRLRVDVJOCL-FQRUVTKNSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08005</td>
      <td>4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide</td>
      <td>ARMFMDYRYOKSOW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08459</td>
      <td>3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile</td>
      <td>SVMHTBVIPYVDIL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB02473</td>
      <td>6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine</td>
      <td>XRHANBWAKSYPEN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12267</td>
      <td>Brigatinib</td>
      <td>AILRADAXUVEEIR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08003</td>
      <td>ISOTHIAZOLIDINONE ANALOG</td>
      <td>UILYPHAKDBTKQV-UFYCRDLUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB04477</td>
      <td>N-1,2,3,4-Tetrahydronaphth-1-Yl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine</td>
      <td>FDZQGEIYGFPMOB-ZUURFMEUSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12731</td>
      <td>Daporinad</td>
      <td>KPBNHDGDUADAGP-VAWYXSNFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB12307</td>
      <td>Foretinib</td>
      <td>CXQHYVUVSFXTMY-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB09074</td>
      <td>Olaparib</td>
      <td>FDLYAMZZIXQODN-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12781</td>
      <td>Balaglitazone</td>
      <td>IETKPTYAGKZLKY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06967</td>
      <td>6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE</td>
      <td>MLSVRCGEBXIIQO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB15444</td>
      <td>Elexacaftor</td>
      <td>MVRHVFSOIWFBTE-INIZCTEOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB06925</td>
      <td>3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE</td>
      <td>YEIASMOUYNOXGA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB07204</td>
      <td>(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE</td>
      <td>DQIXTEDFNFZMCM-SFHVURJKSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06908</td>
      <td>(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID</td>
      <td>PAWOPJKHTZCKMT-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB06334</td>
      <td>Tucidinostat</td>
      <td>SZMJVTADHFNAIS-BJMVGYQFSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12857</td>
      <td>NVP-LEQ-506</td>
      <td>POERAARDVFVDLO-QGZVFWFLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB07215</td>
      <td>2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID</td>
      <td>ILUPZUOBHCUBKB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08974</td>
      <td>Flubendazole</td>
      <td>CPEUVMUXAHMANV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB08446</td>
      <td>3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile</td>
      <td>OHQMEDBYNUAVNE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB12682</td>
      <td>Mubritinib</td>
      <td>ZTFBIUXIQYRUNT-MDWZMJQESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB07216</td>
      <td>(11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE</td>
      <td>ZMGCFGGMTCMSDP-QHCPKHFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB06393</td>
      <td>Xaliproden</td>
      <td>WJJYZXPHLSLMGE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB06494</td>
      <td>Sufugolix</td>
      <td>UCQSBGOFELXYIN-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06869</td>
      <td>1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE</td>
      <td>BMHVHOJXEQTIEA-SIKLNZKXSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB06876</td>
      <td>N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE</td>
      <td>YJWJKKXGAPWLGT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB06962</td>
      <td>(5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone</td>
      <td>YKTUSHSSKIWDRY-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB04607</td>
      <td>PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE</td>
      <td>UQAWGIKJINAKIZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6LZG</td>
      <td>DB03712</td>
      <td>RU85053</td>
      <td>CEKLBQMULVLLTD-VMPREFPWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB08402</td>
      <td>2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID</td>
      <td>VNDRRWBKNSHALL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.6</td>
      <td>6CS2</td>
      <td>DB13347</td>
      <td>Diphenadione</td>
      <td>JYGLAHSAISAEAL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11743</td>
      <td>Ipatasertib</td>
      <td>GRZXWCHAXNAUHY-NSISKUIASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15028</td>
      <td>MK-1064</td>
      <td>CKTWQGHVNRYNCM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB03916</td>
      <td>4-{2-[4-(2-Aminoethyl)Piperazin-1-Yl]Pyridin-4-Yl}-N-(3-Chloro-4-Methylphenyl)Pyrimidin-2-Amine</td>
      <td>RHOOHUMOHVIXEF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04888</td>
      <td>Bifeprunox</td>
      <td>CYGODHVAJQTCBG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08300</td>
      <td>1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine</td>
      <td>UOKGZPYGRJDACN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07676</td>
      <td>3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one</td>
      <td>CKLAPOFDFZKCPB-LBPRGKRZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08429</td>
      <td>N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide</td>
      <td>QRGBOABBMKYMLG-UXHICEINSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB08504</td>
      <td>6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM</td>
      <td>ZNHVIJAGMFQGMS-IHPCNDPISA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02647</td>
      <td>N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide</td>
      <td>LUCORKWTQSQFFU-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB00897</td>
      <td>Triazolam</td>
      <td>JOFWLTCLBGQGBO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>1R42</td>
      <td>DB02258</td>
      <td>SR11254</td>
      <td>RNZIUDLOJHVHLZ-VYIQYICTSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02615</td>
      <td>Compound 19</td>
      <td>UZOOIPXOYYJULJ-BLIZRMSTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11772</td>
      <td>Pilaralisib</td>
      <td>QINPEPAQOBZPOF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB08531</td>
      <td>5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>CVYWYUAQFJMLEO-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08531</td>
      <td>5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>CVYWYUAQFJMLEO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08534</td>
      <td>5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>ZAIYYXVHGBMLEC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04862</td>
      <td>Merimepodib</td>
      <td>JBPUGFODGPKTDW-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB03672</td>
      <td>9-N-Phenylmethylamino-Tacrine</td>
      <td>JYJAEHAURXXPSD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08489</td>
      <td>N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE</td>
      <td>GCBPAPVOMPJQHK-NQIIRXRSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB08538</td>
      <td>N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>HQPVGVSQPQVZLD-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6lu7</td>
      <td>DB11904</td>
      <td>Flumatinib</td>
      <td>BJCJYEYYYGBROF-UHFFFAOYSA-N</td>
      <td>active site</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB08406</td>
      <td>[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE</td>
      <td>NXCCIJQEAKMFGW-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB02651</td>
      <td>{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)</td>
      <td>BTAGTGWPDROBMG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07728</td>
      <td>2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE</td>
      <td>XJJYJNMNYDNXNO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>1R42</td>
      <td>DB02449</td>
      <td>3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid</td>
      <td>ULOTXPTWJAUGGE-MHZLTWQESA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08500</td>
      <td>(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol</td>
      <td>ZCJBDRSKHARECB-PYTCMNEWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>1R42</td>
      <td>DB02483</td>
      <td>Etheno-Nad</td>
      <td>JCDBQDNBEQHDHK-BSLNIGMPSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11753</td>
      <td>Rifamycin</td>
      <td>HJYYPODYNSCCOU-ODRIEIDWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02336</td>
      <td>RU83876</td>
      <td>WCMLXBUNHNAMNH-UIOOFZCWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08463</td>
      <td>(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol</td>
      <td>HOCBJBNQIQQQGT-LJQANCHMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07962</td>
      <td>METHYL N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINATE</td>
      <td>ZMRRBWRMQPQQAN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02704</td>
      <td>(2r,3r,4r,5r)-3,4-Dihydroxy-N,N'-Bis[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-2,5-Bis(2-Phenylethyl)Hexanediamide</td>
      <td>GQKBYZPVKVXMJL-LAFNQVRVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07872</td>
      <td>5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide</td>
      <td>IYGIXVNAMZPBDK-CQSZACIVSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11176</td>
      <td>Zeaxanthin</td>
      <td>JKQXZKUSFCKOGQ-QAYBQHTQSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09020</td>
      <td>Bisacodyl</td>
      <td>KHOITXIGCFIULA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04669</td>
      <td>TRIAZOLOPYRIMIDINE</td>
      <td>YWBFPKPWMSWWEA-UHFFFAOYSA-O</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09017</td>
      <td>Brotizolam</td>
      <td>UMSGKTJDUHERQW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04424</td>
      <td>RPR128515</td>
      <td>XFKVLKLCLYJKNF-MZNJEOGPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04405</td>
      <td>2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid</td>
      <td>AQYSXARQCHHHLK-NRFANRHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB00502</td>
      <td>Haloperidol</td>
      <td>LNEPOXFFQSENCJ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11274</td>
      <td>Dihydro-alpha-ergocryptine</td>
      <td>PBUNVLRHZGSROC-VTIMJTGVSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15229</td>
      <td>CNV-2197944</td>
      <td>BLFJGFDZMABYMY-ZDUSSCGKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08980</td>
      <td>Fendiline</td>
      <td>NMKSAYKQLCHXDK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11363</td>
      <td>Alectinib</td>
      <td>KDGFLJKFZUIJMX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04330</td>
      <td>Bilh 434</td>
      <td>KNRVCCXHLSHTFW-HGPRPZRGSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07839</td>
      <td>N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE</td>
      <td>VFNWTXUFNNOQHD-QFIPXVFZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08930</td>
      <td>Dolutegravir</td>
      <td>RHWKPHLQXYSBKR-BMIGLBTASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB03507</td>
      <td>6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One</td>
      <td>UXGUZFZBZPPZGL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04258</td>
      <td>Seocalcitol</td>
      <td>LVLLALCJVJNGQQ-SEODYNFXSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09034</td>
      <td>Suvorexant</td>
      <td>JYTNQNCOQXFQPK-MRXNPFEDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09319</td>
      <td>Carindacillin</td>
      <td>JIRBAUWICKGBFE-MNRDOXJOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15281</td>
      <td>Ravoxertinib</td>
      <td>RZUOCXOYPYGSKL-GOSISDBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07945</td>
      <td>5-(3-carbamoylbenzyl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-4-carboxylic acid</td>
      <td>GKBQRPKZHUFGOB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB09195</td>
      <td>Lorpiprazole</td>
      <td>BNRMWKUVWLKDQJ-YJBOKZPZSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04608</td>
      <td>9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE</td>
      <td>IAUZTOZLTFSMIE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09166</td>
      <td>Etizolam</td>
      <td>VMZUTJCNQWMAGF-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09079</td>
      <td>Nintedanib</td>
      <td>XZXHXSATPCNXJR-ZIADKAODSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB09079</td>
      <td>Nintedanib</td>
      <td>XZXHXSATPCNXJR-ZIADKAODSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07994</td>
      <td>N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE</td>
      <td>KMBPJSHPAXOXBT-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15367</td>
      <td>LY-2623091</td>
      <td>YPCLDHGBEKZGEB-RUDKWAFVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04632</td>
      <td>4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE</td>
      <td>JHHBGNIRSUTQAS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09292</td>
      <td>Sacubitril</td>
      <td>PYNXFZCZUAOOQC-UTKZUKDTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04645</td>
      <td>5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID</td>
      <td>NJJIFGCFUDDBSP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09073</td>
      <td>Palbociclib</td>
      <td>AHJRHEGDXFFMBM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07917</td>
      <td>4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE</td>
      <td>TZQGXAHOROZEKN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB09042</td>
      <td>Tedizolid phosphate</td>
      <td>QCGUSIANLFXSGE-GFCCVEGCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04434</td>
      <td>Naphthyridine Inhibitor</td>
      <td>YRBHUKMLAGQYHS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02498</td>
      <td>Carba-Nicotinamide-Adenine-Dinucleotide</td>
      <td>DGPLSUKWXXSBCU-VGXGLJSLSA-O</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15219</td>
      <td>Tomivosertib</td>
      <td>HKTBYUWLRDZAJK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB08912</td>
      <td>Dabrafenib</td>
      <td>BFSMGDJOXZAERB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08100</td>
      <td>2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol</td>
      <td>PAHKYLUYTGBFNW-CMDGGOBGSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02388</td>
      <td>Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine</td>
      <td>UQFRSHRWRKYNDE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08111</td>
      <td>4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol</td>
      <td>ZGJYGQLGSXWEMY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11663</td>
      <td>Pictilisib</td>
      <td>LHNIIDJUOCFXAP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11686</td>
      <td>Iferanserin</td>
      <td>UXIPFQUBOVWAQW-UEBLJOKOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB00430</td>
      <td>Cefpiramide</td>
      <td>PWAUCHMQEXVFJR-PMAPCBKXSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11692</td>
      <td>Pavinetant</td>
      <td>QYTBBBAHNIWFOD-NRFANRHFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB01100</td>
      <td>Pimozide</td>
      <td>YVUQSNJEYSNKRX-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB01070</td>
      <td>Dihydrotachysterol</td>
      <td>ILYCWAKSDCYMBB-OPCMSESCSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08706</td>
      <td>(2S)-({(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}AMINO)(4-FLUOROPHENYL)ACETIC ACID</td>
      <td>RNEACARJKXYVND-MZLJFPOFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>1R42</td>
      <td>DB00872</td>
      <td>Conivaptan</td>
      <td>IKENVDNFQMCRTR-UHFFFAOYSA-N</td>
      <td>ACE2 area with important AAs</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07787</td>
      <td>5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE</td>
      <td>PNPFDRCIGCUCMN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB08683</td>
      <td>REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE</td>
      <td>OTPNDVKVEAIXTI-IYBDPMFKSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04006</td>
      <td>[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone</td>
      <td>WUGJIPFLBOATGL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07779</td>
      <td>N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE</td>
      <td>ANQHSFFUNMTTRS-MOPGFXCFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB01254</td>
      <td>Dasatinib</td>
      <td>ZBNZXTGUTAYRHI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04760</td>
      <td>PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(4-FLUORO-3-METHYL-BENZYLAMIDE)</td>
      <td>PYFRREJCFXFNRR-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04759</td>
      <td>PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(3-METHYL-BENZYLAMIDE)</td>
      <td>GTBUZLPQANSGGE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11611</td>
      <td>Lifitegrast</td>
      <td>JFOZKMSJYSPYLN-QHCPKHFHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB04724</td>
      <td>(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE</td>
      <td>COVPLULNDBDXTN-KYJUHHDHSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15209</td>
      <td>MK-0736</td>
      <td>ORQZQBUNAMJFCY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15456</td>
      <td>Vericiguat</td>
      <td>QZFHIXARHDBPBY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15193</td>
      <td>BMS-955176</td>
      <td>XDMUFNNPLXHNKA-ZTESCHFWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11431</td>
      <td>Moxidectin</td>
      <td>YZBLFMPOMVTDJY-LSGXYNIPSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB04232</td>
      <td>N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide</td>
      <td>DNGGPLKVDUPXFN-GOSISDBHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02505</td>
      <td>N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)</td>
      <td>JJVQUUYZGJWBPW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB03962</td>
      <td>Nicotinamide 8-Bromo-Adenine Dinucleotide Phosphate</td>
      <td>MDKMTCCUJSRQGW-NAJQWHGHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB00482</td>
      <td>Celecoxib</td>
      <td>RZEKVGVHFLEQIL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15187</td>
      <td>Dubermatinib</td>
      <td>YUAALFPUEOYPNX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15177</td>
      <td>VX-659</td>
      <td>IGEOJNMYRZUKIK-IBGZPJMESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB01215</td>
      <td>Estazolam</td>
      <td>CDCHDCWJMGXXRH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11511</td>
      <td>Difloxacin</td>
      <td>NOCJXYPHIIZEHN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08833</td>
      <td>Taurochenodeoxycholic acid</td>
      <td>BHTRKEVKTKCXOH-BJLOMENOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB15169</td>
      <td>H3B-6527</td>
      <td>MBWRLLRCTIYXDW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB01218</td>
      <td>Halofantrine</td>
      <td>FOHHNHSLJDZUGQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08061</td>
      <td>4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE</td>
      <td>GELALLNTKKLQLM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11822</td>
      <td>TMC-647055</td>
      <td>UOBYJVFBFSLCTQ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB08285</td>
      <td>(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol</td>
      <td>SQUNOCMDMIQIQK-OAHLLOKOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12491</td>
      <td>Fasiglifam</td>
      <td>BZCALJIHZVNMGJ-HSZRJFAPSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB01708</td>
      <td>Prasterone</td>
      <td>FMGSKLZLMKYGDP-USOAJAOKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06134</td>
      <td>SNS-314</td>
      <td>FAYAUAZLLLJJGH-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12050</td>
      <td>LY-3039478</td>
      <td>YCBAQKQAINQRFW-UGSOOPFHSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12415</td>
      <td>Galeterone</td>
      <td>PAFKTGFSEFKSQG-PAASFTFBSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07415</td>
      <td>4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine</td>
      <td>RFLOFHKRBGKCOB-AWEZNQCLSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12027</td>
      <td>Serdemetan</td>
      <td>CEGSUKYESLWKJP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07125</td>
      <td>4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid</td>
      <td>KKZYGUVAFJCULH-CYBMUJFWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07124</td>
      <td>(2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE</td>
      <td>CCIACUJJBPSOHE-KRWDZBQOSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB01830</td>
      <td>{4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid</td>
      <td>SPSGYTWOIGAABK-DQEYMECFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB05959</td>
      <td>ENMD-1198</td>
      <td>YQJWOUQGXATDAE-ACNBBOPNSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07107</td>
      <td>(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE</td>
      <td>SGHXFHRRWFLILP-XJDXJNMNSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12477</td>
      <td>Perfluoro tert-butylcyclohexane</td>
      <td>VLTXBOGHSBHSAC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07074</td>
      <td>6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER</td>
      <td>OUBRALHIKGRAMA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12010</td>
      <td>Fostamatinib</td>
      <td>GKDRMWXFWHEQQT-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06347</td>
      <td>Cenisertib</td>
      <td>KSOVGRCOLZZTPF-QMKUDKLTSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB14067</td>
      <td>Dofequidar</td>
      <td>KLWUUPVJTLHYIM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07459</td>
      <td>4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE</td>
      <td>HVLSCZSVTCNAQX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07039</td>
      <td>(2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide</td>
      <td>RXSZCFAPSDTELY-SFHVURJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07041</td>
      <td>N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide</td>
      <td>FDJWFDQRPKKBFA-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB00157</td>
      <td>NADH</td>
      <td>BOPGDPNILDQYTO-NNYOXOHSSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12540</td>
      <td>Lecozotan</td>
      <td>NRPQELCNMADTOZ-OAQYLSRUSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07063</td>
      <td>{3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID</td>
      <td>KYHVTMFADJNSGS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB14626</td>
      <td>Pregnenolone acetate</td>
      <td>CRRKVZVYZQXICQ-RJJCNJEVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB13113</td>
      <td>JNJ-38877605</td>
      <td>JRWCBEOAFGHNNU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07065</td>
      <td>5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine</td>
      <td>AHPKUZJCNHGFQA-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07514</td>
      <td>3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one</td>
      <td>LHLGUOHREUTYTO-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB14152</td>
      <td>Ginsenosides</td>
      <td>NLHQJXWYMZLQJY-SWIZOJJJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12505</td>
      <td>E-7820</td>
      <td>LWGUASZLXHYWIV-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06652</td>
      <td>Vicriviroc</td>
      <td>CNPVJJQCETWNEU-CYFREDJKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB05932</td>
      <td>Denibulin</td>
      <td>GAOHLWCIAJNSEE-JTQLQIEISA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07072</td>
      <td>(1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE</td>
      <td>CNKRZILQBKJWDS-WMFXKJRFSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB05678</td>
      <td>SLx-4090</td>
      <td>AZUIUVJESCFSLJ-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB06595</td>
      <td>Midostaurin</td>
      <td>BMGQWWVMWDBQGC-IIFHNQTCSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07159</td>
      <td>Tamatinib</td>
      <td>NHHQJBCNYHBUSI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12401</td>
      <td>Bromperidol</td>
      <td>RKLNONIVDFXQRX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06497</td>
      <td>Aplaviroc</td>
      <td>GWNOTCOIYUNTQP-FQLXRVMXSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB13422</td>
      <td>Nicofuranose</td>
      <td>FUWFSXZKBMCSKF-ZASNTINBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB13710</td>
      <td>Metenolone</td>
      <td>ANJQEDFWRSLVBR-VHUDCFPWSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12289</td>
      <td>Darexaban</td>
      <td>IJNIQYINMSGIPS-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB13676</td>
      <td>Mosapramine</td>
      <td>PXUIZULXJVRBPC-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12280</td>
      <td>AZD-5423</td>
      <td>FCNQMDSJHADDFT-WNSKOXEYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB03072</td>
      <td>2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone</td>
      <td>LOFDUAJQRUYHBR-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB00590</td>
      <td>Doxazosin</td>
      <td>RUZYUOTYCVRMRZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12211</td>
      <td>PSI-697</td>
      <td>DIEPFYNZGUUVHD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB02152</td>
      <td>K-252a</td>
      <td>KOZFSFOOLUUIGY-SOLYNIJKSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07253</td>
      <td>N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine</td>
      <td>QTFCKBFCXDAZIU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12247</td>
      <td>AZD-4547</td>
      <td>VRQMAABPASPXMW-HDICACEKSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB07255</td>
      <td>N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE</td>
      <td>PNEWIQAEGKQNCE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB06367</td>
      <td>Relacatib</td>
      <td>BWYBBMQLUKXECQ-GIVPXCGWSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB13649</td>
      <td>Proquazone</td>
      <td>JTIGKVIOEQASGT-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11952</td>
      <td>Duvelisib</td>
      <td>SJVQHLPISAIATJ-ZDUSSCGKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB13756</td>
      <td>Peruvoside</td>
      <td>PMTSPAGBAFCORP-HBUONDEYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12174</td>
      <td>CUDC-101</td>
      <td>PLIVFNIUGLLCEK-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02081</td>
      <td>Bis-Benzamidine</td>
      <td>BXYGSMRTHHSAHZ-PMACEKPBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12096</td>
      <td>PF-05175157</td>
      <td>BDXXSFOJPYSYOC-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12108</td>
      <td>Taselisib</td>
      <td>BEUQXVWXFDOSAQ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06533</td>
      <td>Ragaglitazar</td>
      <td>WMUIIGVAWPWQAW-XMMPIXPASA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB03337</td>
      <td>1-(2-Amidinophenyl)-3-(Phenoxyphenyl)Urea</td>
      <td>ZHCAYBOLUMAUQX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12379</td>
      <td>Indirubin</td>
      <td>CRDNMYFJWFXOCH-BUHFOSPRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB06510</td>
      <td>Muraglitazar</td>
      <td>IRLWJILLXJGJTD-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07334</td>
      <td>N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE</td>
      <td>HTIZPBXCJPQDEM-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12371</td>
      <td>Siponimod</td>
      <td>KIHYPELVXPAIDH-HNSNBQBZSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB13276</td>
      <td>Idanpramine</td>
      <td>HVYGXNYMNHSBGD-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB03076</td>
      <td>AHA047</td>
      <td>CGBDAHCDSVOMCF-FYZVQMPESA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12141</td>
      <td>Gilteritinib</td>
      <td>GYQYAJJFPNQOOW-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12355</td>
      <td>Netazepide</td>
      <td>YDZYKNJZCVIKPP-VWLOTQADSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12339</td>
      <td>Radezolid</td>
      <td>BTTNOGHPGJANSW-IBGZPJMESA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB02197</td>
      <td>4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide</td>
      <td>NKORVPQBJCGYEC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB05490</td>
      <td>AMG-131</td>
      <td>NMRWDFUZLLQSBN-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB00197</td>
      <td>Troglitazone</td>
      <td>GXPHKUHSUJUWKP-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12914</td>
      <td>MGL-3196</td>
      <td>FDBYIYFVSAHJLY-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12742</td>
      <td>Amuvatinib</td>
      <td>FOFDIMHVKGYHRU-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12899</td>
      <td>TT-301</td>
      <td>ZPJGUEPHFXPAQF-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB00783</td>
      <td>Estradiol</td>
      <td>VOXZDWNPVJITMN-ZBRFXRBCSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB11923</td>
      <td>Decoglurant</td>
      <td>DMJHZVARRXJSEG-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12836</td>
      <td>Grapiprant</td>
      <td>HZVLFTCYCLXTGV-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07642</td>
      <td>5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine</td>
      <td>GYKIQIOWVKCVBP-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12764</td>
      <td>ABC-294640</td>
      <td>CAOTVXGYTWCKQE-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB05294</td>
      <td>Vandetanib</td>
      <td>UHTHHESEBZOYNR-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB03157</td>
      <td>N,O-Didansyl-L-Tyrosine</td>
      <td>LUBOPDUYHWABFG-NDEPHWFRSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06948</td>
      <td>2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE</td>
      <td>XWWRLKIBRPJQJX-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12729</td>
      <td>ASP-3026</td>
      <td>MGGBYMDAPCCKCT-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11912</td>
      <td>Lanopepden</td>
      <td>SWHNZGMQMGFQGW-MSOLQXFVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB01876</td>
      <td>Bis(5-Amidino-2-Benzimidazolyl)Methanone</td>
      <td>VVVXDHROXQUONB-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12725</td>
      <td>TD-8954</td>
      <td>MZOITCJKGUIQEI-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12720</td>
      <td>Nivocasan</td>
      <td>VYFGDLGHHBUDTQ-ZLGUVYLKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12651</td>
      <td>Bardoxolone</td>
      <td>TXGZJQLMVSIZEI-UQMAOPSPSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12867</td>
      <td>Benperidol</td>
      <td>FEBOTPHFXYHVPL-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB05424</td>
      <td>Canertinib</td>
      <td>OMZCMEYTWSXEPZ-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06847</td>
      <td>5-[(3S)-3-(2-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine</td>
      <td>YYCPXVRHQUEVAW-CQSZACIVSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06831</td>
      <td>2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE</td>
      <td>UMMYTDJYDSTEMB-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06721</td>
      <td>Gimatecan</td>
      <td>UIVFUQKYVFCEKJ-OPTOVBNMSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12659</td>
      <td>SJ-733</td>
      <td>VKCPFWKTFZAOTO-LEWJYISDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB05450</td>
      <td>Smilagenin</td>
      <td>GMBQZIIUCVWOCD-UQHLGXRBSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB11939</td>
      <td>Henagliflozin</td>
      <td>HYTPDMFFHVZBOR-VNXMGFANSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB01938</td>
      <td>L-Histidine Beta Naphthylamide</td>
      <td>DKDILZBBFKZMRO-OAHLLOKOSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12780</td>
      <td>Quinfamide</td>
      <td>SBJGFIXQRZOVTO-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12703</td>
      <td>Omipalisib</td>
      <td>CGBJSGAELGCMKE-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB05465</td>
      <td>Tandutinib</td>
      <td>UXXQOJXBIDBUAC-UHFFFAOYSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB12972</td>
      <td>Sepranolone</td>
      <td>AURFZBICLPNKBZ-FZCSVUEKSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12949</td>
      <td>PF-03382792</td>
      <td>AGMOFKKOVMRGAK-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB07651</td>
      <td>N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE</td>
      <td>KPMMESISHWWXNM-ROUUACIJSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6LZG</td>
      <td>DB12591</td>
      <td>BMS-911543</td>
      <td>JCINBYQJBYJGDM-UHFFFAOYSA-N</td>
      <td>ACE2 - CoV spike complex</td>
    </tr>
    <tr>
      <td>-8.5</td>
      <td>6CS2</td>
      <td>DB06888</td>
      <td>(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE</td>
      <td>KBLPHMRCKHFBJB-OLZOCXBDSA-N</td>
      <td>ACE2 area for S-protein binding</td>
    </tr>
  </tbody>
</table>
	
	</div>

	<!-- Copyright links, logos-->	
	<div id="copyright">
		<p>
			<a href="http://www.rnasa-imedir.udc.es/en/"><img alt="RNASA-IMEDIR" src="images/rnasa_imedir.png" id="footerimg"></a>
			<a href="https://www.fic.udc.es/"><img alt="FIC" src="images/fic.png" id="footerimg"></a>
			<a href="https://www.citic.udc.es/"><img alt="CITIC" src="images/citic.png" id="footerimg"></a>
			<a href="https://www.udc.es/en/"><img alt="UDC" src="images/udc.png" id="footerimg"></a>
			<a href="http://www.rnasa-imedir.udc.es/en/"><img alt="INIBIC" src="images/inibic.png" id="footerimg"></a>
		</p>
	
		<p>&copy; <a href="https://sites.google.com/view/rnasa-imedir-covid19/">RNASA-IMEDIR</a> | Created by <a href="https://sites.google.com/site/muntisa/publications">Cristian R Munteanu</a></p>
	</div>

</body>

</html>